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THESIS SUMMARY 
 
The work contained in this thesis would not have been possible without the 
collaboration from local clinicians and support from local private enterprises 
within the Launceston community. During the course of this PhD, 
immunohistochemistry and immunofluorescence confocal microscopy 
techniques were developed which are now routinely used by the Mucosal 
Immunology team, located within the School of Health Sciences at UTAS, 
Newnham. 
A key initiating event in the development of Inflammatory Bowel Diseases (IBD) 
is thought to be activation of the inflammasome complex and therefore the aim 
of this study was to examine the mRNA expression of inflammasome component 
and their cellular localisation in remission and active IBD. The structure of the 
thesis includes a General Introduction, a Material and Methods Chapter, followed 
by three Research Chapters and a General Discussion. With this thesis design 
there is however some repetition, particularly in the introduction sections, due 
to the similarity of background material. 
In summary, Chapter 3 of this thesis details the mRNA expression of targeted 
inflammasome genes in biopsies obtained from ulcerative colitis (UC) and 
Crohn’s disease (CD) patients. The most exciting finding related to this work was 
the disease specific upregulation of NLRP6 in ileal CD, which was confirmed by 
both qRT-PCR performed at UTAS and RNA sequencing performed independently 
at Ramaciotti Centre for Genomics in Sydney.  
Chapter 4 reports research focused on the AIM2 inflammasome. From Chapter 3 
it was established that the expression of AIM2 increased with disease activity in 
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UC and CD. Using immunohistochemistry and immunofluorescence confocal 
microscopy AIM2 was localised to epithelial cell layer, specifically to the 
intraepithelial lymphocytes, which are cells at the forefront of immune defences. 
Chapter 5  details the cellular localisation and spatial relationship of NLRP3 and 
Interleukin (IL)-1β and  follows on from the upregulation of NLRP3 and IL-1β in 
active disease, demonstrated in Chapter 3.  In general, NLRP3 was found to be 
predominantly expressed in neutrophils and other immune cells of the lamina 
propria. NLRP3 is generally regarded as a global sensor because of its ability to 
process IL-1β in response to a wide range of pathogenic, sterile and cell stress 
activators. The product of inflammasome activation, IL-1β is a potent 
inflammatory cytokine responsible for many local and systemic responses. In the 
normal colon, inflammasome dependent caspase-1 was found to contribute to the 
production of mature IL-1β. Surprisingly and novel to this research was the 
reduced contribution of the NLRP3 inflammasome to IL-1β production in active 
UC. Given the dominance of a neutrophil lamina propria cell population in active 
UC it was likely that neutrophil derive serine proteases contributed more than 
the NLRP3 inflammasome to the overall IL-1β production.   
In the murine system, NLRP6 has been shown to regulate goblet cell mucin 
production and secretion, regulate epithelial self-renewal and proliferation, 
protect against chemical induced intestinal injury and tumorigenesis, and 
negatively regulate inflammasome signalling. In contrast, human studies 
examining the expression and activity of NLRP6 remain limited.  
Chapter 6 details research carried on from the disease specific upregulation of 
NLRP6 in ileal CD and describes the colonic localisation of NLRP6 and MUC2 in 
active and remission IBD. In ileal CD, NLRP6 was localised to the epithelial cell 
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layer, myofibroblasts and lamina propria immune cells. Consistent with clinical 
observation MUC2 was increased in CD and reduced in active UC. The 
identification of a high NLRP6 expressing goblet cell localised to the apical region 
of the intestinal crypt was a novel and exciting finding. Furthermore, the effect of 
NLRP6 induction on MUC2 expression in human colonic cell lines was a new 
avenue of investigation and demonstrated the repression of MUC2 expression 
with NLRP6 induction. The relationship of NLRP6 to MUC2 and E-cadherin was 
intriguing and will be the focus of future research. 
In conclusion, this research project has described the colonic localisation of AIM2, 
NLRP3, IL-1β, MUC2 and NLRP6 in the normal colon, remission and active UC and 
CD. Novel findings include;  
1. The disease  specific upregulation of NLRP6 in active ileal CD. 
2. The identification of a NLRP6 expressing goblet cell localised 
predominantly in the upper portion of the intestinal crypt, which suggests 
a possible role for NLRP6 in goblet cell expulsion. 
3. The intraepithelial lymphocyte localisation of AIM2  in normal, remission 
and active disease which suggests AIM2 is geared to provide immediate 
and heightened immune protection. 
4. The reduced contribution of NLRP3 to IL-1β in active UC suggests 
neutrophil- derived serine proteases are likely the source of bioactive IL-
1β and caspase-1 has only a minor role. 
Altogether, this study has provided an insight into the activity of inflammasome 
in human IBD. NLRP6 can now be considered a potential marker for 
distinguishing ileal CD from colonic CD and terminal ileum involved UC. Future 
work needs to address if there is a therapeutic benefit in switching on NLRP6 in 
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active UC or if disabling NLRP6 improves disease activity in ileal CD. Similarly, is 
there a therapeutic benefit in blocking both caspase-1 and neutrophil derived 
serine proteases in active UC? 
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THESIS ABSTRACT 
 
Ulcerative colitis (UC) and Crohn’s disease (CD) are characterised by chronic and 
recurrent inflammation of the gastrointestinal tract. The development of  
Inflammatory Bowel Diseases (IBD) is regarded as a multifactorial disease 
process involving a combination of immune system defects and environmental 
influences, which occur in the genetically predisposed individual. In the gut, the 
multimolecular complex known as the inflammasome is a key mediator in 
regulating the host’s immune response to invading pathogens and/or cellular 
stress. Formation of the inflammasome complex provides a platform for the 
caspase-1 dependent activation of the potent inflammatory cytokines, 
interleukin (IL)-1β and IL-18. Dysregulation of the inflammasome complex is 
thought to contribute to IBD pathogenesis. 
Quantitative RT-PCR, RNA-sequencing, immunohistochemistry and  
immunofluorescence confocal microscopy were used to examine the mRNA 
expression  and cellular localisation of inflammasome forming components in 
colonic biopsies obtained from IBD and control patients. Rosiglitazone induced 
NLRP6 expression was performed in the colonic cell lines, LS174T and HT29 to 
investigate the effect of NLRP6 on MUC2 expression. 
Novel findings from this research include the disease specific upregulation of 
NLRP6 in active ileal CD. The identification of a NLRP6 expressing goblet cell 
localised predominantly in the upper portion of the intestinal crypt. Repression 
of MUC2 expression with increased expression of NLRP6 in the human colorectal 
adenocarcinoma cell line, LS174T. The localisation of AIM2 to the intraepithelial 
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lymphocytes and the reduced contribution of NLRP3-dependent caspase-1 to 
bioactive IL-1β production in active UC.   
In conclusion, NLRP6 can now be considered a potential marker for 
distinguishing ileal CD from colonic CD and terminal ileum involved UC. 
Furthermore, results of this study will direct future work examining if there is a 
therapeutic benefit in switching off NLRP6 in active ileal CD, or blocking both 
caspase-1 and neutrophil-derived serine protease production of IL-1β in active 
UC. 
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CHAPTER 1 GENERAL INTRODUCTION  
 
1.1 INTRODUCTION 
The human gut is a 24 hours a day, 365 days a year continuous system that is 
responsible for converting the food we eat into the energy our bodies need to 
grow and develop. It helps with the removal of waste material by forming stools 
and plays an important role in protecting us from infection by fighting harmful 
bacteria, viruses and cancer cells. The gut is home to millions of microorganisms, 
many of which aid intestinal function by stimulating the digestive process and the 
absorption of nutrients [1].  
The luminal contents of the gut are bound by three distinct cellular layers, the 
mucosa, submucosa and the muscularis propria. The lamina propria extends from 
the subepithelial basement membrane complex to the muscularis propria and is 
composed of various types of leucocytes, extracellular matrix and fibroblasts [2] 
(Figure 1-1).  
At the mucosa surface numerous pathogenic microbes and environmental toxins 
challenge the vast array of immune cells within the lamina propria to direct and 
shape the body’s immune system. The immune system consists of two equally 
important aspects, the innate immunity and the adaptive immunity. Both are 
important for maintaining defences but differ with respect to response time, 
central cell types and specificity for different classes of microbes. 
The components of the innate immune system include the physical epithelial 
barriers that prevent infection, the leucocytes, proteins and mechanisms that are 
always present and ready to fight infection and the cytokines and chemokines, 
which recruit phagocytic cells to the site of infection. These responses are quickly 
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activated and are dependent on the recognition of pathogenic insult or cellular 
stress [3]. 
In contrast, the adaptive immune system lacks the ability to respond to infection 
immediately but acts on pathogens that have evaded and overcome the innate 
immune responses. There are two types of adaptive immune responses, humoral 
immunity, mediated by antibodies produced by B lymphocytes and cell-mediated 
immunity, mediated by T lymphocytes. Both cause proliferation of effector cells 
and provide a potent mechanism for neutralising and eliminating pathogens. 
Adaptive immunity creates immunological memory and confers long lasting 
protection for the body against the reinfection of specific pathogens [4]. 
The main challenge of the gut immune system is to remain unresponsive to the 
microorganisms that participate in the digestive process while regulating a 
dynamic microbial population that is easily influenced by lifestyle factors such as 
diet, medication, age and illness. When dysbiosis of the resident microbial 
population occurs, infection and malabsorption can often follow, and this can be 
a contributing factor in the development of gastrointestinal disease. 
Diseases characterised by chronic and relapsing inflammation of the 
gastrointestinal tract are known as inflammatory bowel diseases (IBD).  The two 
main types of IBD are ulcerative colitis (UC) and Crohn’s disease (CD). The 
mechanisms that lead to the development of these diseases is still unclear, 
however it is generally regarded as a multifactorial disease process involving a 
combination of immune system defects and environmental influences which 
occur in the genetically predisposed individual [2]. 
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Figure 1-1: The Structure of the colonic mucosa within the human gut.  
The epithelial cell layer of the gut separates the contents of the gut lumen from 
the immune cells of the lamina propria and is comprised of absorptive 
enterocytes, goblet cells, Paneth cells and enteroendocrine cells. Goblet cells 
contribute to the protective mucus layer and promote the elimination of gut 
contents [5]. The lamina propria immune cells, such as dendritic cells, 
neutrophils, monocytes, lymphocytes and macrophages either detect pathogens 
or are recruited to the site of infection or injury to initiate downstream innate 
and adaptive immune system pathways that promote pathogen elimination and 
tissue repair [2] (image adapted from Kim, Y and Ho, S [5]). 
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1.2 INFLAMMATORY BOWEL DISEASES 
In Australia, it is estimated that IBD affects 1 in 250 people aged 5-49 and that by 
the year 2020 more than 92,000 people will be diagnosed with the disease. In 
2012, the management of IBD was estimated to cost Australia, $270 billion with 
a loss of productivity at around $380 million [6]. Australia along with other 
western, industrialised countries such as United States, Canada, New Zealand and 
certain European Countries have the highest prevalence of IBD while Asian 
countries report the lowest incidence and prevalence [7-9].  
The symptoms of IBD can vary, but in general patients usually present with one 
or more of the following; watery or bloody diarrhoea, rectal bleeding, faecal 
incontinence, abdominal pain, tenesmus (pain when passing stools), faecal 
urgency, fever, weight loss, malnutrition and lethargy [10-13]. In addition, more 
than 30% of IBD patient experience other chronic inflammatory disease such as 
primary sclerosing cholangitis, ankylosing spondylitis, psoriasis and arthritis [2, 
10].  
In the absence of infectious causes, a diagnosis of UC or CD involves the 
combination of clinical, laboratory, radiographic and endoscopic observations. 
Multiple endoscopic mucosal biopsies are useful for assessing disease activity 
and the identification of pre-cancerous lesions in UC, however in CD they tend not 
to be as useful because CD lesions frequently occur adjacent to normal mucosa 
[11, 14].  
UC primarily affects the mucosa and submucosa layers of the large intestine. 
Usually the disease begins at the anal verge and spreads proximally in a diffuse 
and continuous manner along the length of the colon. In Pancolitis the 
inflammation extents along the entire length of the colon to the ileocaecal valve 
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and occasionally involves the terminal ileum [11]. The gross appearance varies 
with disease activity but in general, there is evidence of mucosal erosion, mucin 
depletion, oedema, petechial haemorrhages and mucosal ulcers or lesions of 
varying size [15]. 
 Microscopically, UC is characterised by structural abnormalities of the mucosa 
and increased intensity of lamina propria cellular infiltrates with alteration in 
composition and change in distribution. Often neutrophils within epithelial 
structures, such as crypt wall (cryptitis), crypt lumen (crypt abscess) or 
associated with crypt destruction indicates active disease. Other features such as 
paneth cell metaplasia, diffuse thickening of the muscularis mucosae may help 
confirm diagnosis [16]. 
In contrast, the inflammation in CD is discontinuous and transmural and can 
affect any area of the gastrointestinal tract, from mouth to anus. The most 
common sites are the terminal ileum, colon and ileo-caecal region, while 
involvement of the upper gastrointestinal tract is uncommon [11]. In CD, the 
length of involved disease is variable and lesions are separated by uninvolved 
‘skip areas’. The gross appearance of the mucosa is often heterogeneous with 
multiple aphthoid lesions. Over time these lesions confluent both transversely 
and longitudinally to give the mucosa the distinctive cobblestone appearance. 
Ulcerations can give rise to strictures, abscesses or deeply situated fissuring 
ulcers which reach adjacent organs, all of which are not normally seen in UC [10]. 
Preserved or increased mucin secretion is also a feature of CD [11]. 
Microscopic assessment of disease activity in CD is difficult because of the 
segmental and transmural nature of the disease and biopsies of early lesions 
(preaphthoid lesions) do not yield diagnostic information. Features that favour 
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CD are epithelioid granulomas, bowel wall thickening, discontinuous 
inflammation, mucin preservation at the edge of an ulcer, relatively unchanged 
crypt architecture or patchy crypt atrophy and changes in the intensity of 
distribution of lamina propria inflammatory cells [11, 17]. 
When treating IBD patients the focus is always to induce and maintain clinical 
remission with progressive intensification of therapy as the disease worsens 
[18]. Current treatment options include a combination of, antibiotics, vitamin 
support, immunomodulators, corticosteroids, 5-aminosalicylates, biologic 
therapies and surgery [11, 19]. It is not uncommon for CD patients to undergo 
multiple surgeries to control reoccurring disease while in UC, removal of the 
colon and rectum will not only eliminate disease but also removes the risk of 
colorectal cancer developing. 
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1.3 GENETIC RISK FACTORS 
IBD is a complex polygenic disorder with complex inheritance. An individual’s 
genetic background is known to not only influence disease onset, but also the 
phenotype, the location and the disease course [20]. Using genome-wide 
association studies (GWAS) and subsequent meta-analyses a total of 240 loci 
have been identified as reaching significance thresholds and being associated 
with disease development [21]. While many of these loci contain multiple genes, 
others contain no genes. Of the 240, 110 are known to contribute to both 
phenotypes, 30 are Crohn’s disease specific loci and 23 are ulcerative colitis 
specific [22]. Notably many loci overlap with the susceptibility to other 
inflammatory diseases such as ankylosing spondylitis and psoriasis, while others 
have been implicated in mechanisms such as, bacterial sensing, epithelial 
defence, cytokine signalling and autophagy [22]. Of the polygenic disorders IBD 
is unusual in that it has provided replicate genetic susceptibility using both GWAS 
and linkage studies [10].  
Combining GWAS studies and the greater concordance in monozygotic twins for 
CD than UC it appears the contribution of genetic factors may be more important 
in CD than UC [20, 23]. The general theme emerging for CD involves one of 
defective processing of intracellular bacteria with innate immunity and 
autophagy genes such as NOD2, IRGM, ATG16L1 being CD specific associations. 
While in UC, defects in epithelial barrier function highlighted by gene associations 
with HNF4A, LAMB1, CDH1 and GNA12 are thought to influence disease 
development [24]. 
The many number of genes that confer susceptibility to both CD and UC such as 
those involved in IL23/Th17 signalling (IL23R, IL12B, JAK2, TYK2, STAT3, IL10, 
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IL1R2, REL, CARD9, NKX2.3, ICOSLG, PRDM1, SMAD3 and ORMDL3) suggest 
common pathways may also be responsible for disease pathogenesis [24]. 
Considered important to the development of these diseases are the missense 
polymorphisms, such as single nucleotide polymorphisms(SNPs) that mediate 
mRNA changes that result in protein structure or function alterations. 
Noteworthy, is many of these protein-coding regions are often distant from their 
gene regulatory regions [25]. 
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1.4 ENVIRONMENTAL RISK FACTORS 
The recent emergence of IBD in developing countries combined with the 
variability of disease presentation with geographical location suggests that 
environmental influences may contribute to disease development. Urbanisation 
of societies and adoption of western culture has led to changes in diet, increased 
antibiotic use, improved hygiene, better vaccination rates and increased 
pollutant exposure, all of which have been highlighted as potential risk factors, 
however most are poorly defined [26, 27]. 
Smoking and appendectomy are two well established risk factors for IBD, which 
impact on the course of the disease but fail to correlate with the incidence or 
prevalence of the disease. For instance, Canada and Sweden have a high incidence 
of CD with a low prevalence of smokers while Africa and Asia have a high 
prevalence of smokers with a low incidence of CD [27]. For CD patients, smoking 
results in a worse disease course and more recurrent disease flare-ups while in 
UC, smoking is protective for development of the disease and UC patients who 
smoke experience a milder disease course [28-32].  
For UC patients, appendectomy before the age of 20 is considered protective. 
Patients diagnosed after appendectomy have a more limited disease extent with 
fewer clinical relapses when compared to patients with an intact appendix [33-
36]. The protective nature of appendectomy on CD remains unclear with several 
studies showing a positive effect [34] while others demonstrate no association 
[37-39]. Neither smoking or appendectomy have been shown to be necessary or 
causative for the development of IBD [40]. 
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1.5 THE INNATE IMMUNE SYSTEM 
1.5.1 INTESTINAL EPITHELIAL BARRIER  
The epithelial cell layer separates the luminal contents of the bowel from the 
immune cells of the lamina propria and is often the first site of exposure for many 
of the environmental and pathogenic factors that contribute to disease pathology. 
The development of the epithelial cell layer begins with multipotent stem cells 
located within the epithelial invaginations known as the crypts of Lieberkühn 
[20]. Intermingling with multipotent stem cells are paneth cells, which have 
originated from undifferentiated stem cells. Under the direction of Wnt and Notch 
signalling pathways epithelial stem cells differentiate into absorptive 
enterocytes, mucus-producing goblet cells and hormone-secreting 
enteroendocrine cells and migrate from the crypts to the intestinal villi [41].  
The integrity of the epithelial barrier is maintained by intercellular junctions on 
the lateral cell surface which anchor cell-cell contacts to the actomyosin 
cytoskeleton [42]. Movement through the junctions is by paracellular 
permeability based on size, osmotic or electrical gradients and is controlled by a 
variety of different host, dietary and microbial factors. Cytokines like IL-10 and 
transforming growth factor-β (TGF-β) enhance tight junction while inflammatory 
cytokine like IL-1β, IL-4, IL-13, tumor necrosis factor-α (TNF-α) and IFN-ɣ 
degrade tight junction permeability by altering the claudin composition [20, 43, 
44]. Increased epithelial permeability is a well-established consequence of 
mucosal inflammation and considered an important contributor to the 
development of gastrointestinal diseases. Remarkably, prior to disease relapse 
CD patients demonstrate increased intestinal permeability, [45, 46] while UC 
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patients experience more disease relapses with increased intestinal permeability 
[47].  
 
1.5.2 PATHOGEN RECEPTORS OF THE INNATE IMMUNE SYSTEM 
The innate immune system is the “danger sentinel” of the gut  and maintains 
mucosal homeostasis by using an array of germline-encoded pattern recognition 
receptors to continually scan the cellular  and luminal environments [48]. Pattern 
recognition receptors primarily recognise conserved microbial molecules known 
as pathogen-associated molecular patterns (PAMPs) or damage-associated 
molecular patterns (DAMPs) released in response to stress, tissue damage and 
necrotic cell death [49-51]. Cells involved in first-line defence mechanisms such 
as dentritic cells, epithelial cells, monocytes, macrophages and neutrophils are all 
known to express pattern recognition receptors [48].  
Membrane bound pattern recognition receptors, such as Toll-like receptors 
(TLRs) and C-type lectin receptors (CLRs) are responsible for monitoring the 
extracellular milieu and endosomal compartments for PAMPs and DAMPs. While 
cytoplasmic surveillance is executed by NOD-like receptors (NLRs), pyrin and 
HIN domain containing (PYHIN) family members, RIG-1-like receptors (RLRs) 
and several cytosolic nucleic acid sensors [52]. Membrane and intracellular 
receptors work in concert with one another to orchestrate an effective immune 
response against a potential pathogenic insult. Often an intact microbial pathogen 
will contain multiple PAMPs which trigger the sequential detection by a number 
of receptors in different subcellular compartments [53].  
Pattern recognition receptors have the ability to promote the secretion of 
proinflammatory cytokines, transcription mediators, and initiate pathways 
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responsible for pathogen neutralisation and elimination [54]. In addition, some 
receptors are known to form the structural backbone of the multimolecular 
complex known as the inflammasome.  
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1.6 THE INFLAMMASOME COMPLEX 
The inflammasome complex is a core component of the inflammatory response 
and its activation enhances the maturation of proIL-1β and proIL-18 to their  
biologically active IL-1β and IL-18 forms [48]. Transcription of proIL-1β is 
induced by TLR and CLR stimulation via the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-кB) transcription pathway, whereas proIL-18 
is constitutively expressed and its expression is increased after receptor 
activation [55, 56]. For activated macrophages and monocytes of the lamina 
propria inflammasome maturation of IL-1β and IL-18 is crucial for cytokine 
secretion [57].  
In the intestine, the inflammasome can also promote an inflammatory form of cell 
death, known as pyroptosis. Pyroptosis halts the replication of intracellular 
pathogens by destroying the infected immune cell and exposing the surviving 
bacteria to circulating phagocytes and neutrophils [58]. Both canonical (caspase-
1) and non-canonical (caspase-11) inflammasome pathways are able to induce 
pyroptosis, however caspase-11 does not produce mature IL-1β or IL-18. 
Caspase-11 induced pyroptosis is thought to occur upstream of canonical 
inflammasomes in response to lipopolysaccharides (LPS) sensed in Gram-
negative bacteria. Both mechanisms are considered important for microbial 
defences in the gut [58, 59]. 
In addition to inflammasome-dependent production of IL-1β, several cell specific 
inflammasome-independent processes exist for the activation of IL-1β. During 
acute inflammation, neutrophil derived serine proteases, proteinase 3, elastase 
and cathepsin G can process proIL-1β to biologically active IL-1β [60-63].  
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1.6.1 FORMATION OF A NOD-LIKE RECEPTOR PROTEIN (NLRP) 
INFLAMMASOME COMPLEX 
In general, the NOD-like receptor protein (NLRP) inflammasome complex 
consists of a nucleotide-binding oligomerisation domain (NOD)-like receptor 
(NLR) protein, a caspase and often an adaptor protein known as apoptosis-
associated speck-like protein containing a CARD (ASC) [48, 64]. Several receptors 
from the NLR family, NLRP1, NLRP2, NLRP3, NLRC4, NLRP6, NLRP7 and NLRP12 
(Figure 1-2) have all shown the ability to form the structural backbone of an 
inflammasome complex. The ASC adaptor protein is identical for all 
inflammasomes and contains two transduction domains, a pyrin domain (PYD) 
domain and a caspase recruitment domain (CARD) domain [65].  
Formation of a NLRP inflammasome is initiated by ligand activation of the 
receptor protein and this causes the NLR proteins to oligomerise through their 
nucleotide binding and oligomerisation (NACHT) domains (Figure 1-3). This 
oligomerisation creates a platform of NLRPYD molecules at the N-terminal and 
through NLRPYD/ASCPYD interactions nucleates helical ASC clusters to form an ASC 
filament structure. The aggregation of multiple ASCCARD molecules promotes 
ASCCARD/caspase-1CARD interactions, which in turn brings caspase domains into 
close proximity for dimerisation, trans-autocleavage and activation [65]. The 
binding of ASC to both the NLR protein and caspase-1 is facilitated by a 23-
residual linker which orientates ASCPYD and ASCCARD back to back hence 
preventing steric interference of binding sites, while enhancing binding partner 
prospects [66]. ASC is sequestered in the nucleus but rapidly translocates to the 
cytoplasm upon stimulation where it participates in inflammasome formation 
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[67]. Interestingly, inflammasome formation can be abolished by preventing the 
cellular redistribution of ASC [67]. 
Caspase-1 is synthesised as an inactive, monomeric zymogen (procaspase-1) and 
initially is cleaved into a p35 fragment containing a CARD and p10 fragment. 
Autoproteolysis results in the generation of a large p20 subunit and a small p10 
subunit and the removal of the N-terminal CARD domain. Dimerisation of caspase 
molecules (p20 and p10) results in the catalytically active caspase-1 enzyme 
(Figure 1-4) [68, 69]. Inflammasome activated caspase-1 cleaves its substrates, 
proIL-1β and proIL-18 at recognition sites adjacent to aspartic acid residues, 
resulting in mature IL-1β and IL-18 [64].  
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Figure 1-2: Structure of the human NOD-like receptor subgroups 
The NOD-like receptor (NLR) family comprises 23 human members [20, 70]. All 
NLR proteins contain a central nucleotide binding and oligomerisation (NACHT) 
domain flanked by a C-terminal LRR domain and N-terminal effector domain. The 
NACHT domain facilities self-oligomerisation and has ATPase activity. The N-
terminal domain participates in protein-protein interactions while the LRR 
domain is involved in ligand recognition. Subgroup classification is based on the 
structure of the N-terminal effector region, which generally comprises a CARD, 
PYD or BIR domain. The NLRP1, NLRP2, NLRP3, NLRC4, NLRP6, NLRP7 and 
NLRP12 receptors have all shown the ability to form inflammasome complexes. 
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 In contrast to other members of the NLRP subfamily, NLRP1 contains both a 
function-to-find (FIIND) and CARD domain at the C-terminal, and a PYD domain 
at the N-terminal [71] (Figure 1-2). Given that NLRP1 contains two signal 
transduction domains (PYD and CARD) it can activate caspase-1 through its C-
terminal CARD domain without the need for the ASC adaptor protein, however 
ASC has been shown to greatly enhance inflammasome formation and IL-1β 
processing [72]. The FIIND domain is a highly conserved protein region and 
based on amino acid sequencing is only present in two human proteins, NLRP1 
and the caspase recruitment domain family, member 8 (CARD8) protein [73]. 
CARD8 is thought to function as an adaptor molecule that negatively regulates 
NF-кB activation, caspase-1 dependent IL-1β secretion and apoptosis, and is 
often overexpressed in many types of cancers [74-76]. 
NLRP1 inflammasome formation is strictly dependent on autolytic proteolysis 
within the FIIND domain and after cleavage, the two fragments remain associated 
to form a processed NLRP1. Dimers of ASC joined by ASCPYD/ASCPYD are recruited 
to the C-terminal NLRCARD domain and bind via NLRCARD/ASCCARD interactions. 
This is in contrast to other NLRP proteins which recruit ASC to the N-terminal 
PYD domain and bind via NLRPYD/ASCPYD interactions to form the inflammasome 
complex. Subsequently, caspase-1 through its CARD domain interacts with 
ASCCARD which leads to dimerisation, trans-autocleavage and activation of 
caspase-1 and IL-1β, IL-18 processing [77]. The formation of ASC filaments in the 
activation of the NLRP1 inflammasome remain to be defined. 
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Figure 1-3: Formation of a NOD-like receptor protein inflammasome 
containing an N-terminal pyrin domain 
Formation of a nucleotide-binding oligomerisation domain (NOD)-like receptor 
protein (NLR) inflammasome is initiated by ligand activation of the NLR protein. 
This causes the NLR proteins to oligomerise through their NACHT domains to 
create a platform of NLRPYD molecules at the N-terminal and through 
NLRPYD/ASCPYD interactions, nucleates helical ASC clusters to form a filament ASC 
structure. The aggregation of multiple ASCCARD molecules promotes 
ASCCARD/caspase-1CARD interactions which in turn brings caspase domains into 
close proximity for dimerisation, trans-autocleavage, activation and the 
processing of proIL-1β and proIL-18 to their biologically active forms, IL-1β and 
IL-18 respectively. 
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Figure 1-4: The mechanism for the inflammasome mediated catalytic 
conversion of procaspase-1 to caspase-1 
Caspase-1 is initially synthesised as the inactive monomeric zymogen, 
procaspase-1. Binding of the procaspase-1CARD to ASCCARD filaments on the 
inflammasome complex results in the cleavage of procaspase-1 into a p35 
fragment containing a CARD and a p10 fragment. Dimerisation of the p10 and p20 
and the removal of the procaspase-1CARD domain produces catalytically active 
caspase-1. 
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1.6.2 STRUCTURE AND FORMATION OF A PYRIN AND HIN DOMAIN 
(PYHIN) INFLAMMASOME COMPLEX 
Two receptor in the pyrin and hematopoitic interferon-inducible nuclear 
proteins (HIN) (PYHIN) receptor family, absent in melanoma 2 (AIM2) and 
interferon inducible protein 16 (IFI16) have shown the ability to form 
inflammasome complexes [68, 78] (Figure 1-5).  Similar to NLRP inflammasomes, 
PYHIN inflammasomes, such as AIM2, upon ligand activation oligomerise through 
their PYD domains to form a platform of AIM2PYD molecules, which preferentially 
associates with ASCPYD to form ASC filaments. The flexibly linked ASCCARD clusters 
along the ASCPYD to form a platform for the binding of caspase-1CARD. Similar to 
other NLRP inflammasomes, the ASC filament structure forms the main body of 
the inflammasome. The interaction of ASCCARD/caspase-1CARD brings caspase 
domains into close proximity for dimerisation, trans-autocleavage and activation, 
and the subsequent maturation of IL-1β and IL-18 [65]. 
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Figure 1-5: Structure of the human pyrin and HIN domain (PYHIN) 
family 
The human pyrin and hematopoitic interferon-inducible nuclear proteins (HIN) 
(PYHIN) family of receptors comprises 4 members including, the interferon 
inducible protein 16 (IFI16), absent in melanoma 2 (AIM2), myeloid nuclear 
differentiation antigen (MNDA) and interferon inducible protein X [IFIX 
(Pyhin1)], while mouse contains 11 confirmed members [79]. All members 
consist of an N-terminal pyrin domain (PYD) domain attached to one or more 
hemopoietic interferon-inducible nuclear protein (HIN-200) domains at the C-
terminal. Three distinct forms of HIN-200 have been characterised (HIN-A, -B and 
-C) and are classified according to specific consensus motifs [80]. 
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1.7 LIGAND SENSING OF INFLAMMASOME COMPLEXES 
Depending on the type of receptor protein in the complex, inflammasomes have 
the ability to respond to a wide array of pathogens and cellular danger signals. 
The LRR domains of the NLRP receptors and the HIN200 domains of the PYHIN 
receptors are thought to be involved in ligand interactions, however direct 
binding of an activating ligand to a receptor has only been demonstrated for the 
AIM2 and IFI16 inflammasomes.  
 
1.7.1 THE NLRP1 INFLAMMASOME 
The NLRP1 inflammasome was one of the first inflammasomes to be described 
however, efforts to unravel the processes that lead to activation have been 
hampered by species variations in the NLRP1 gene. In humans the NLRP1 gene is 
singular, while in mouse the gene encoding Nlrp1 is polymorphic with three 
homologs, Nlrp1a, Nlpr1b and Nlrp1c [68]. Furthermore, the structure of mouse 
Nlrp1 lacks the N-terminal PYD domain found in human NLRP1 and five different 
strain specific Nlrp1b alleles exist in inbred mice [81]. 
Nlrp1 is activated mainly by lethal toxin (LeTx) produced by Bacillus anthracis 
with variations in Nlrp1b providing sensitivity or resistance to the toxin [82]. 
LeTx is a bipartite toxin consisting of a protective antigen binding subunit and a 
catalytic lethal factor moiety. Binding of the protective antigen to anthrax binding 
sites translocates lethal factor into the host cytosol where it cleaves the N-termini 
of mitogen-activated protein kinase (MAPK) thereby disrupting cell signalling 
pathways. Initially lethal factor blocks cytokine production from numerous cell 
types, inhibits chemotaxis of neutrophils, induces apoptosis in activated 
macrophages and later induces cytokine-independent shock and death [83]. 
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Caspase-1 and IL-1β deficient mice are more susceptible to B.anthracis infection 
indicating IL-1β production via the NLRP1b inflammasome is more important 
than ASC independent pyroptosis in the host protective response to B.anthracis 
[69, 83].     
More recently, NOD2 has been linked to NLRP1 dependent sensing of bacterial 
muramyl dipeptide (MDP) and B.anthracis in activated cells where it produces a 
NOD2-NLRP1 inflammasome complex [84]. NOD2 is a known intracellular sensor 
of MDP and has the ability to contribute to the induction of NF-кB and MAPK 
transcription factors, however TLRs are much more effective in triggering these 
responses [85]. The absence of NOD2 prevents B. anthracis induced IL-1β 
secretion but has little effect on the transcription of proIL-1β indicating the 
importance of the NOD2-NLRP1 association in host defences against B. anthracis 
[84].  
 
1.7.2 THE NLRP3 INFLAMMASOME 
The NLRP3 inflammasome has the ability to activate upon exposure to a wide 
range of whole pathogens, environmental irritants and structurally diverse 
DAMPs and PAMPs [48, 49, 86]. 
While the mechanisms are not yet fully understood it is thought that activation of 
NLRP3 occurs in response to host derived factors that are altered by these agents. 
While several models have been proposed for the activation of NLRP3 none have 
been found to be unified for all activating agents. The proposed mechanisms 
include;  
1. K+ efflux [87] 
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2. The generation of mitochondrial derived reactive oxygen species (mROS) 
[88] 
3. Phagolysosomal destabilisation and the release of cathepsins [89] 
4. The release of mitochondrial DNA or the mitochondrial phospholipid 
cardiolipin [90-92] 
5. Translocation to the mitochondria [88, 93, 94]  
To add to the controversy, membrane permeation, phagolysosmal 
destabilisation, mitochondrial damage and ROS production are all interrelated 
cellular events making the distinction between bystander and causative 
activation events complicated. 
In resting cells, the basal expression of NLRP3 is insufficient for inflammasome 
activation and consequently two signals are required for the activation of the 
NLRP3 inflammasome [95, 96]. The first signal is the NF-кB mediated 
transcription of NLRP3 and proIL-1β from stimulation of TLR antagonists or 
cytokines such as TNF-α and IL-1β. The second signal is the ligand activation step 
which culminates in the activation of caspase-1 and the maturation of IL-1β and 
IL-18 [49, 97]. The enhanced effect of guanylate binding protein (GBP5) on Nlrp3 
inflammasome assembly in response to bacteria and soluble but not crystalline 
inflammasome priming agents raises the possibility of agent specific cofactors 
being required for inflammasome activation [98].  
Particulate matter such as aluminium, silica, monosodium urate (MSU), calcium 
pyrophosphate dehydrate crystals, cholesterol and amyloid β enters the cell by 
means of phagocytosis [89, 99-101]. The destabilisation of the phagolysosmal 
membrane and the release of the cysteine protease cathepsins B into the cytosol 
is thought to also trigger NLRP3. Inhibitors of cathepsins B have been shown to 
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prevent caspase-1 activation induced by N. gonorrhoeae [102]. Interestingly, 
cathepsins deficient mice show minimal defects in the activation of NLRP3 in 
response to particulate matter, suggesting other off target effects may exist [103]. 
More recently, mitochondrial dysfunction and activation of the NLRP3 
inflammasome has been an area of intense research and much speculation.  mROS 
are produced in response to cell stresses such as, hypoxia, starvation, pathogen 
infection, and growth factor stimulation or membrane damage [104]. The release 
of mROS and oxidised mitochondrial DNA have both been shown to activate the 
NLRP3 inflammasome [90, 105]. Interruption of ROS production using inhibitors 
blocks NLRP3 activation suggesting ROS production upstream is necessary for 
NLRP3 activation [105-107]. 
It has been proposed that NLRP3 associates with the mitochondria upon 
activation [93, 105] and when exposed to non-crystalline activators, recruitment 
from the cytosol to the mitochondria is mediated by the mitochondrial anti-viral 
signalling protein (MAVS) [94]. MAVS is also known as a mitochondrial adaptor 
protein and plays a crucial role in RLR receptor signalling pathways leading to 
type 1 IFN induction and NF-кB activation [108]. MAVS is thought to directly 
associate with the N-terminus of NLRP3 to promote optimal inflammasome 
formation [94]. Consistent with a role for MAVS in NLRP3 activation, MAVS 
deficient mice exposed to dextran sodium sulphate (DSS) induced colitis fail to 
upregulate IL-1β [109].  
Other work on mitochondrial dysfunction has demonstrated a ROS independent 
activation of Nlrp3 induced by the antibiotic linezolid whereby the mitochondrial 
specific lipid cardiolipin binds to Nlrp3 leading to the maturation of IL-1β [92]. 
Cardiolipin is a phospholipid exclusively found in the inner mitochondrial 
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membrane of eukaryotic cells. Cardiolipin plays a critical role in the activation of 
caspase-8 and caspase-3 in the apoptotic cell death pathway, which raises the 
possibility that the inflammasome pathways are linked to the apoptosis pathways 
by processes that control mitochondrial homeostasis.  
In addition, agents that induce NLRP3 activation, such as nigericin have 
demonstrated an ability to disrupt mitochondrial homeostasis by reducing the 
intracellular concentration of the coenzyme NAD+. Low NAD+ inactivates the α-
tubulin deacetylase sirtuin 2 (SIRT2) and causes the accumulation of acetylated 
α-tubulin. Excess acetylated α-tubulin mediates the microtubule transport of 
mitochondria, which drives the apposition of ASC on the mitochondria to NLRP3 
on the endoplasmic reticulum. Microtubule transport of organelles creates 
optimal sites for signal transduction between ASC and NLRP3 and directs 
activation of NLRP3. Work using inhibitors of tubulin polymerisation have 
demonstrated suppression of IL-1β [93]. 
Early work investigating caspase-1 activation by the NLRP3 inflammasome 
showed that K+ efflux accompanies NLRP3 activation [106, 110]  and a high 
extracellular concentration of K+ blocks the activation of not only the NLRP3 
inflammasome but also the NLRP1, NLRC4 and AIM2 inflammasomes [111, 112]. 
ATP levels have been linked to K+ efflux, such that high extracellular ATP levels 
engage the ATP-gated purinergic P2X7 receptor promoting the formation of the 
pannexin-1 pore, which induces K+ efflux [97, 113]. Previous work by Muῆoz-
Planillo [87] has shown that ROS generation, opening of the pannexin-1 pore and 
K+ efflux all occur upon stimulation with a variety of bacterial pore-forming 
toxins, nigericin, ATP and particulate matter. However in contrast to others the 
permeation of the cell membrane to K+  and Na+ was found to be the only 
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common step induced by all NLRP3 antagonists and the primary activity that was 
necessary and sufficient for caspase-1 activation. In addition, cytosolic K+ efflux 
was found to be specific to NLRP3 activation and was shown not to play a role in 
the activation of AIM2. These results await further clarification by other 
independent researchers. 
 
1.7.3 THE NLRC4 INFLAMMASOME 
The NLRC4 inflammasome has been well characterised in the mouse system and 
plays an important role in the detection of pathogenic bacteria [68]. The 
pathogenicity of a bacteria is reliant on functional secretion systems including the 
type III and IV which act as needle-like structures delivering virulent factors into 
the host’s cytosol. NLRC4 is activated by two critical components of pathogenic 
bacteria, a sequence motif found in the basal rod components of the type III 
(T3SS) and IV (T4SS) bacterial secretion systems, and a similar sequence motif 
found in flagellin, which is a component of their flagellum apparatus [114, 115]. 
NLRC4 has been shown to detect basal rod components in Salmonella 
typhimurium, Legionella pneumophila, Burkholderia pseudomallei, Escherichia 
coli, Shingella flexneri, Pseudomonas aeruginosa [116, 117] and leaked cytosolic 
flagellin from Listeria monocytogenes, Salmonella typhimurium, Pseudomonas 
aeruginosa and Legionella pneumophila [115, 118, 119]. 
Activation of the NLRC4 inflammasome involves the initial binding of a receptor 
protein from the neuronal apoptosis inhibitory protein (NAIP) subfamily of NLRs 
to the activating ligand. NAIP receptor proteins differ from other NLRs in that 
they contain multiple BIR domains at the N-terminus instead of a CARD or PYD 
domain (Figure 1-2). In humans, only one NAIP homolog is expressed, whereas 
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in mice, the NAIP locus is polymorphic and seven paralogs of Naip (Naip1-Naip7) 
exist [117]. Human NAIP and its mouse ortholog, Naip1 recognise cytosolic T3SS 
needle proteins, Naip2 binds T3SS rod components while Naip5 and Naip6 bind 
directly to bacterial flagellin [117, 119]. Binding of a NAIP protein to a bacterial 
motif leads to the formation of the NAIP-NLRC4 inflammasome complex and 
activation of caspase-1.  
Interestingly, in human U937 monocyte derived macrophages NLRC4 activation 
does not occur in response to flagellin or T3SS rod protein but occurs in response 
to the T3SS subunit Cprl from Chromobacterium violaceum, which raises the 
possibility that other accessory proteins may be involved in activation of the 
human NLRC4 inflammasome [119]. 
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1.7.4 THE AIM2 AND IFI16 INFLAMMASOME 
Both the cytosolic AIM2 receptor and the nuclear IFI16 receptor directly bind 
their activating ligand double stranded DNA (dsDNA) via the C terminal HIN200 
domain [120-122].  Non-sequence specific binding occurs at multiple sites along 
the dsDNA and is through electrostatic attractions between the positively 
charged HIN domain residues and the dsDNA sugar phosphate backbone [123].  
The mechanisms that enable AIM2 and IFI16 to respond to viral, bacterial, 
mammalian and synthetic dsDNA while remaining unresponsive to self DNA are 
still unclear [68, 124].  
Work using Aim2 deficient mice have demonstrated an essential role for AIM2 in 
the recognition of viruses and bacteria by the detection of cytosolic dsDNA. When 
compared to WT mice, Aim2-/- mice experience higher mortality rates, higher 
bacterial loads and decrease production of caspase-1 generated cytokines after 
infection with Fransicella tularenis, suggesting AIM2 is necessary for detection of 
Fransicella tularenis [125, 126].  Similarly, mouse macrophages deficient for 
Aim2 show an impaired ability to recognise not only Fransicella tularenis, but 
also vaccinia virus, murine cytomegalovirus (mCMV) with only partial 
recognition of Listeria monocytogenes being demonstrated [120, 127].    
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1.7.5 THE NLRP6, NLRP7 AND NLRP12 INFLAMMASOMES 
In addition to the well-known NLRP1, NLRP3, NLRC4, AIM2 and IFI16 
inflammasomes NLRP6, NLRP7 and NLRP12 have shown an ASC-dependent 
activation of caspase-1. However, the signals that activate the NLRP6 and 
NLRP12 inflammasomes are yet to be determined [128].  
Indeed, two independent studies have reported caspase-1 activation and IL-1β 
release in Nlrp6 deficient mouse macrophages in response to ATP and LPS, which 
suggest the triggers that activate the NLRP6 inflammasome are different to those 
that activate the NLRP3 inflammasome [129, 130]. Recently NLRP7, which is not 
expressed in mice, was shown to form an ASC-dependent inflammasome in 
human macrophages in response to microbial acylated lipopeptides [131].  
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1.8 REGULATION OF THE INFLAMMASOME COMPLEX 
The potent inflammatory cytokines, IL-1β and IL-18 and the pyroptosis pathway 
all have the potential to cause tissue damage and disrupt an effective adaptive 
immune response. The mechanisms that lead to maturation of IL-1β and IL-18 
are tightly controlled at several levels and multiple checkpoints along this 
process ensuring response appropriate levels.    
In most cells the basal levels of many of the inflammasome constituents is 
insufficient for inflammasome formation. Consequently, the expression of the 
inflammasome components is regulated by NF-кB induced transcription and 
requires sensitisation by a TLR or CLR ligand or stimulus from cytokine signalling 
pathways [49, 50]. In contrast to most cytokines, IL-1β and IL-18 are produced as 
inactive zymogens requiring caspase-1 cleavage between Asp and Ala for 
maturation [55, 132]. The synthesis of precursor cytokines requiring activation 
prevents aberrant secretion of the leaderless IL-1β and IL-18 cytokines. Serine 
proteinases such as cathepsins G, elastase and in particular proteinase 3 found in 
neutrophils have also been shown to cleave proIL-1β to active IL-1β. While in 
monocytes autocrine production of ATP can activate caspase-1 and cleave proIL-
1β, thereby releasing IL-1β by transcription only [60]. Worth noting is that during 
acute inflammatory conditions non-canonical maturation of IL-1β can also occur 
via caspase-11 and the NLRP3 inflammasome [58].  
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1.8.1 REGULATION BY AUTOINHIBITION OF THE LIGAND SENSING 
DOMAIN 
For most of the receptor proteins autoinhibition of the ligand sensing domain 
prevents unproductive intramolecular interactions by providing a tight on-site 
repression of the protein in the absence of a suitable activating ligand.  For 
NLRP1, NLRP3, NLRP12 and NLRC4 receptors autoinhibition is achieved by the 
association of two chaperone proteins, ubiquitin ligase-associated protein 
(SGT1) and heat-shock protein 90 (HSP90) to the LRR domain. Upon ligand 
sensing, SGT1 and HSP90 dissociate resulting in a conformation change within 
the protein which favours the recruitment of the ASC adaptor protein [133]. 
Whether autoinhibition of the sensing region occurs for the NLRP6 protein 
remains to be determined. For the PHYIN subfamily autoinhibition is provided by 
the molecular interactions between the PYD and HIN-200 domain and binding of 
DNA releases this autoinhibition [123].  
 
1.8.2 PRIMING EVENTS THAT REGULATE ACTIVATION 
Specific priming events are known to regulate the activation of inflammasomes. 
The K-63 specific deubiquitinating enzyme BRCC3 mediates the deubiquitylation 
of NLRP3, which has recently been shown to occur in response to pattern 
recognition receptor stimulation [134]. Similarly, and as mentioned above, GBP5 
enhances NLRP3 assembly in response to bacterial but not crystalline agents 
[98]. A priming event involving the phosphorylation of Ser533 by kinases like 
PKCδ is necessary before Salmonella typhimurium can activate the NLRC4 
inflammasome. The phosphorylation of Ser533 is thought to result in a 
conformation change within the NLRC4 protein [135]. 
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The anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma 
extra-large (Bcl-XL) have been shown to regulate the NLRP1 inflammasome. By 
associating with NLRP1 via their loop domains Bcl-2 and Bcl-XL are able to 
suppress caspase-1 activation and IL-1β processing [136, 137]. Similar 
experiments for NLRP3 in Bcl-2 deficient macrophages have shown more 
caspase-1 processing while Bcl-2 overexpressing macrophages demonstrated 
less caspase-1 processing suggesting NLRP3 may also be regulated by Bcl-2 
protein [90].  
Activation of the NLRP3 inflammasomes is thought to be influenced by K+ levels, 
indeed low intracellular K+ level enhance caspase-1 activation [106, 110]. 
Similarly, high extracellular K+ levels block IL-1β release from the NLRC4 and 
AIM2 inflammasome suggesting the regulatory effect of K+ may be extended to 
other inflammasome complexes [125, 138]. Interestingly, the levels of 
extracellular K+ need to block IL-1β release for the NLRP3 inflammasome is less 
than that needed for the NLRC4 or AIM2 complex, while for the NLRP7 
inflammasome high K+ levels only slightly reduced IL-1β release [131]. More 
work is needed to exclude off target effects and to determine the reasons for 
inflammasome specific thresholds to K+ levels. 
 
1.8.3 REGULATION BY POPS AND COPS 
In humans, pyrin only proteins (POPs) and CARD-only proteins (COPs) regulate 
the inflammasome at the level of death fold interactions. With the exception of 
caspase-12, POPs and COPs are lacking from the mouse genome which suggests 
humans have evolved more complex inflammasome regulatory systems [139]. 
The POPs include, POP1 (also known as PYDC1) and POP2 (also known as 
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PYDC2) and both inhibit PYD interactions between the receptor protein and the 
ASC adaptor molecule. POP1 shows a higher homology to ASCPYD than POP2 and 
therefore inhibits inflammasome formation by sequestering ASC from other 
inflammasome forming NLRs [140]. POP2 is surprisingly similar to the PYD 
domain of NLRP2 and NLRP7 and is thought to interact with other NLRPYD 
proteins thereby preventing inflammasome formation [141]. Both POP1 and 
POP2 can prevent NF-кB activation [140, 141].  
The COPS proteins consists of several members including, CARD16 (also known 
as pseudo-ICE or COP1), CARD17 (also known as INCA), CARD18 (also known as 
ICEBERG), caspase-12s and Nod2-S.[142] COP proteins act as decoy inhibitors 
and sequester procaspase-1 via CARD-CARD interactions thereby preventing its 
activation in the inflammasome. For example, CARD 17 is upregulated by IFN-ɣ 
in the monocytic cell lines THP-1 and U937 and interacts with procaspase-1 to 
supress IL-1β processing and release in LPS stimulated macrophages [143]. 
 
1.8.4 REGULATION BY TYPE I INTERFERONS 
Type I interferons restrict IL-1β production by two distinct mechanisms. 
Depending on the cell type, type I interferons through the STAT3 signalling 
pathway can induce autocrine and paracrine production of the anti-inflammatory 
cytokine IL-10 which inhibits the synthesis of proIL-1β and proIL-18. 
Additionally, type I interferons signalling through the STAT1 transcription factor 
can repress the activity of the NLRP1 and NLRP3 inflammasome thereby 
subduing IL-1β production [144]. For the AIM2 inflammasome, Irf3 deficient 
mouse macrophages, which are unable to secrete type I interferons, have 
impaired AIM2 activation in response to Francisella tularensis infection 
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indicating that an intact type I interferon response is required for AIM2 activation 
[125]. Interestingly, activation of the AIM2 inflammasome in response to mouse 
cytomegalovirus does not require an intact type I interferon response [127]. The 
mechanisms pertaining to the selective requirement of type I interferons for the 
clearance of certain infections remain unclear.  
Evidence suggests that cells of the adaptive immune response can also dampen 
inflammasome activation. In mouse macrophages and dendritic cells, effector 
CD4+ T cells and memory T cells suppress activation of the NLRP1 and NLRP3 
inflammasomes. For the NLRP3 inflammasome the inhibitory effect requires the 
cell-to cell contact and could be mimicked by macrophage stimulation with 
members of the TNF family such as, CD40L, OX40L and RANKL. Interestingly, the 
negative feedback loop exerted by T cells is only evident for the NLRP1 and 
NLRP3 inflammasome and was absent for the NLRC4 inflammasome [145].  
 
1.8.5 REGULATION FROM INFLAMMASOME COMPONENTS 
Inflammasomes components can themselves indirectly impact on inflammasome 
formation and IL-1β release. For example, NLRP12 acts as a negative regulator of 
the NF-кB pathway through its interaction and regulation of NIK and TRAF3, and 
dysregulation of NF-кB is associated with colonic inflammation and cancer [146].  
NLRP10 interacts with ASC, even though it lacks a ligand sensing LRR, and is 
thought to negatively regulate the inflammasome by sequestering ASC [147, 148]. 
The ASC adaptor protein, in addition to the full length ASC also exists as three 
novel isoforms, ASC-b, ASC-c and ASC-d. ASC-c exerted an inhibitory effect on 
NLRP3 inflammasome formation by only colocalise with caspase-1 and not 
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NLRP3. ASC-d failed to colocalise with either caspase-1 or NLRP3 suggesting an 
undetermined function for this isoform [67].  
Emerging evidence indicates NLRP7 is able to regulate inflammasomes, however 
conflict reports argue the nature of the negative regulation. Reconstitution 
experiments in HEK293 cells have shown that NLRP7 inhibits NLRP3 and 
caspase-1 mediated release of IL-1β and co-immunoprecipitation studies 
indicated NLRP7 directly interacts with procaspase-1 and proIL-1β [149]. While 
other work focusing on NLRP7 overexpression and gene specific mutations have 
indicated that NLRP7 inhibits NF-кB activation by an unknown mechanism or 
inhibits release of IL-1β [150]. Positive regulation is affirmed by the formation of 
the NLRP7 inflammasome in response to microbial acylated lipopeptides [131]. 
 
1.9 DISEASE ASSOCIATED INFLAMMASOME RELATED VARIANTS  
With regard to IBD, GWAS and met-analysis have identified 240 loci associated 
with disease development [21], however none of these loci involve 
inflammasome forming genes.   
Several inflammatory and autoimmune diseases are linked to inflammasome 
variants and population studies have indicate the potential involvement of 
inflammasome loci in the development of IBD. 
The hereditary periodic fever syndromes known Cryopyrin-associated periodic 
syndromes (CAPS) are associated with the gain of function in NLRP3 which 
causes continuous IL-1β secretion in the absence of an antagonist. CAPS are a 
family of autosomal dominant diseases including, familial cold auto-
inflammatory syndrome (FCAS), Muckle-Wells syndrome, (MWS), and chronic 
infantile neurological, cutaneous and articular, (CINCA) syndrome. The clinical 
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severity of CAPs varies but in general all syndromes are characterised by 
recurrent fever, urticarial-like rashes and systemic inflammation [151]. More 
than 90 disease associated genetic variants of the NLRP3 gene have been 
identified for CAPS, the majority are autosomal dominant missense point 
mutations, located in exon 3, which encodes the NACHT domain [152]. 
Remarkable clinical outcomes for CAPS patients have been achieved by the 
administration of IL-1 blocking agents such as rilonacept (Arcalyst, Regeneron, 
Tarrytown, NY, USA),  canakinumab (Ilaris, Novartis, Basel, Switzerland) and 
anakinra (Kineret, Amgen, Thousand Oaks, CA, USA) [151]. 
The potential involvement of NLRP3 in the pathogenesis of IBD has prompted 
several population studies to examine in depth the genetic region of NLRP3. 
Contributing to CD susceptibility in individuals of European descent is a set of 
SNPs (rs4353135, rs4266924, rs55646866, rs6672995, rs107635144 and 
rs10733133) located in a predicted regulatory region on chromosome 1q44, 
downstream of NLRP3. The risk allele rs4353135 was associated with a decrease 
in NLRP3 expression while rs6672995 was associated with hypoproduction of 
IL-1β [153]. A subsequent study in the UK showed no significant association on 
single locus, subphenotype or haplotype analysis for the above six SNPs with CD 
[154]. Similarly, in a Korean cohort, none of the four NLRP3 SNPs in this study 
were associated with CD or UC. However female UC patients homozygous for the 
rs2043211 SNP encoding the Cys10X in the CARD8 gene, which is the procaspase-
1 recruiting domain of ASC, were significantly associated with high serum IL-1β 
levels [155]. Similar sex difference have been shown in a Swedish cohort where 
the genetic susceptibility of CD in men was associated with combined 
polymorphisms in CARD8 and NLRP3 [156]. Adding to this is the gain of function 
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SNP (Q705K) within the NLRP3 gene which has been associated with increased 
mortality in advanced colorectal cancer patients [157]. 
Given the inconsistencies in population based studies and suggested influence on 
disease progression further studies are warranted to determine the role NLRP3 
variants play in IBD susceptibility and disease phenotypes. 
SNPs in the promoter and coding region of NLRP1 are associated with a high risk 
of developing a variety of diseases such as, generalised vitiligo, vitiligo 
autoimmune diseases, Addison’s disease, type I diabetes, lupus, rheumatoid 
arthritis, autoimmune thyroid disease and Alzheimer disease [158-161]. 
Generalised vitiligo has shown strong association to genetic variations in NLRP1 
with individual carrying two independent risk signals from SNPs at rs6502867, 
rs2670660 and rs8182352 at higher odds ratio (4.2) than individuals carrying a 
high risk allele from only one signal [162]. More recently, SNPs in coding regions 
of NLRP1 (rs11621270) and CARD8 (rs2043211) were found to be associated 
with death and poor disease outcome in bacterial meningitis patients [163].  
Functional studies have suggested multiple roles for CARD8 including, the 
negative regulation of NF-KB,[75] regulation of apoptosis through the inhibition 
of caspase-1, caspase-8 and caspase-9 [74], and lastly as a physical component of 
the inflammasome complex [48].  CARD8 is expressed in the gastrointestinal 
epithelium and lies beneath a GWAS identified peak of linkage for CD on 
chromosome 19q. The rs2043211 SNP changes a cysteine residue to a premature 
stop codon at codon 10 resulting in truncated CARD8 protein which has the 
potential to disrupt not only inflammasome formation but other inflammatory 
mechanisms. The association of the rs2042311 polymorphism to inflammatory 
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bowel disease has been demonstrated in several independent studies which 
suggests CARD8 is a potential candidate gene for IBD [155, 156, 164, 165]. 
Because of IL-18 ability to induce IFN-ɣ and mediate Th1 and Th2 immune 
responses much attention has focused on the genetic associations of IL-18 with 
chronic inflammatory disorders such as, asthma, coronary heart disease, Type I 
diabetes, multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, 
graft-versus-host–disease and Crohn’s disease [166]. While disease specific 
polymorphisms have been identified, the genetic data is largely contradictory and 
divergent associations are numerous reflecting significant genetic heterogeneity 
within groups.  
In the intestine IL-18 is expressed in intestinal epithelial cells, and macrophage 
and dentritic cells of the lamina propria [167]. The human IL-18 gene maps to 
11q22.2–q22.3 and consists of 6 exons and 5 introns spaning over 20.8 kb [168].  
Initial DNA sequencing of the entire coding region of IL-18 failed to identify 
functional mutations however a novel SNP identified as TCA/TCC at codon 35 was 
significantly higher in CD patients than healthy controls and more remarkable in 
females than males [169]. In a Japanese cohort, DNA direct sequencing identified 
a higher frequency of a -137G/C promoter polymorphism in UC proctitis patients 
but no significant difference was detecting in CD patients [170]. However in a 
German cohort the -137 (G/C) polymorphism was not a strong risk factor for IBD 
[171]. More recently, using sequence-specific polymerase chain reaction 
methods the -137 (G/C) SNP and another IL-18 gene promoter SNP, -607 (C/A) 
were identified as being associated with the development of UC but not CD [172]. 
In addition, functional candidate-gene analysis has suggested a strong 
association of the IL18RAP rs917997 SNP to both CD and UC [173].  Similarly, 
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meta-analysis of IL-18 polymorphism and UC identified three polymorphisms, 
rs1946518, rs187238 and rs360718 that may contribute to susceptibility for UC 
among Asians and Africans [174]. Taken altogether, the lack of consistent genetic 
associations for IL-18 suggest promoter polymorphism may impact more on 
disease progression rather than susceptibility. 
Disease association studies for NLRC4 and NAIP variants are limited. A rare 
haplotype in the CARD4/ NLRC4 gene has been reported to be more frequent in 
atopic dermatitis patients than in control patients [175]. A truncated NAIP 
protein has been linked to deregulation of motor neuron apoptosis which 
contributes to the autosomal recessive phenotype known as spinal muscular 
atrophies [176]. More recently, two de novo gain of function mutations in human 
NLRC4, encoding p.Val341Ala and p.Thr337Ser substitutions, situated in the 
NACHT protein domain, are associated with a distinct autoinflammatory disease 
that cosgregates in families [177, 178]. The syndrome presents with 
gastrointestinal complaints, fever and systemic inflammation with varying 
degrees of severity. The genetic defect, now termed NLRC4-macrophage 
activated syndrome (MAS), is thought to result in constitutive activation of the 
NLRC4 inflammasome in macrophages and elevated levels of IL-1β and IL-18 
[178].  
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1.10 INFLAMMASOMES AND THEIR IMPACT ON THE INTESTINAL 
ENVIRONMENT 
Mouse models that stimulate colitis, such as DSS, have provided an accessible 
framework for investigating the role of inflammasomes in diseases that affect the 
gastrointestinal tract. Differences in the experimental conditions used for colitis 
induction and pathogen infection have resulted in many discrepancies regarding 
the redundant or necessary role of individual inflammasome complexes in 
protecting against colitis [71]. 
Mice deficient in Nlrp3, Nlrc4, Il-1β, Casp1/11 and Asc, when challenged by DSS, 
have all shown increased susceptibility to colitis, disease exacerbation, frequent 
mortality and increased tumor formation when compared to DSS challenged wild 
type mice, suggesting these components aid colitis protection [179-185]. Disease 
exacerbation has also been a feature of DSS challenged Nlrp6 deficient mice 
[186]. Not reported in Nlrc4 and Nlrp3 deficient mice but associated with Nlrp6 
deficiency is a reduction in the thickness of the mucus layer and the development 
of a transferable colitis forming microbiota dominated by TM7 and 
Prevotellaceae species (Bacteroidetes phyla). The reduction in mucus has been 
attributed to defects in mucin granule exocytosis and reduce autophagy 
mechanisms in goblet cells which suggests that, unlike NLRP3 and NLRC4, NLRP6 
orchestrates downstream mechanisms involved in bacterial defences [186, 187]. 
NLRP6 is reported to influence the composition of the microbial ecology with 
Nlrp6, Il18, Asc and Casp1 deficient mice developing a colitis forming microbiota 
dominated by TM7 and Prevotellaceae (Bacteroidetes phyla) species [186] 
however these results have been refuted by further work using microbial 
phylogenetic analyses of littermate-controlled experiments [188]. 
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Alterations in the composition of the gut microbiota have been reported for IBD 
patients [189, 190]. In general, UC patients exhibit higher overall bacterial counts 
while in CD the bacterial counts are lower but associated with a higher proportion 
of unclassified Bacteroidetes spp. and a higher diversity of TM7 phylotyes. 
Increases in Enterobacteriaceae, adherent-invasive strains of Escherichia coli 
and Ruminococcus gnavus populations and a decrease in Faecalibacterium and 
Roseburia have been reported for ileal CD [191-193]. Interestingly, disease 
remission in UC induces microbial populations comparable to healthy patients 
while in CD the microbial population is reportedly not altered by disease 
remission, remaining constant in active and quiescent disease states [191]. 
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1.11 AIMS AND HYPOTHESIS 
Inflammasome complexes are core components of the innate immune response 
and are responsible for orchestrating multiple downstream pathways to aid 
pathogen elimination and tissue repair. Dysregulation of the inflammasome 
complex is hypothesised to be a contributing factor in the development of 
gastrointestinal diseases. Research examining the role of inflammasomes in 
human IBD are currently lacking and therefore the overall aim of this study was 
to examine the activity of inflammasomes in human IBD. 
The specific aims of this research are; 
1. To determine the mRNA expression of inflammasome components in 
colon biopsies procured from quiescent and active disease regions using 
qRT-PCR and RNA sequencing. 
2. To examine the cellular localisation of inflammasome receptors and the 
IL-1β cytokine using immunohistochemistry and immunofluorescence 
confocal microscopy. 
3. To investigate the effect of NLRP6 induction on MUC2 expression in 
colonic cell lines. 
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CHAPTER 2 MATERIAL AND METHODS 
 
2.1 ETHICS 
This research was conducted by the University of Tasmania, in collaboration with 
local Gastroenterologists, St Vincent’s Private Hospital, Launceston General 
Hospital and Launceston Pathology. Human studies were approved by the 
University of Tasmania (ethics approval: H11930) and Calvary Health Care of 
Tasmania Clinical and Ethics committee (reference number: 03:09:12). Approval 
letters are provided in Appendix 1 and 2. All participant in this study provided 
informed written consent or parental consent and were aged between 15 and 80 
years. Additional information relating to patient demographics, medication, co-
morbidities, smoking and medical history was collected prior to the procedure 
and confirmed post operation with the treating clinician. Patient participation 
information, medical history and consent forms are provided in Appendix 3 and 
4. To protect the privacy of participants, patient names and personal details were 
blinded from University of Tasmania researchers. 
 
2.2 STUDY PARTICIPANTS AND BIOPSY COLLECTION 
A total of 85 patients presenting for routine colonoscopy investigations between 
June 2012 and June 2014 were recruited for this study. IBD patients were 
excluded if they were experiencing co-existing irritable bowel syndrome (IBS) or 
non-IBD associated gastrointestinal bleeding at the time of colonoscopy. Control 
patients were excluded if they had a previous history of IBD or IBS. 
Of the 85 participants, 30 UC patients and 15 CD patients had colonic biopsies 
taken from both inflamed mucosa and non-inflamed mucosa. Ten UC patients and 
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four CD patients were in remission at the time of colonoscopy and only had 
biopsies taken from non-inflamed mucosa. Four UC and two CD patients 
presented with colonic disease in its entirety and had biopsies taken from only 
inflamed mucosa. Twenty control patients had biopsies collected from healthy 
non-inflamed mucosa. Disease assessment and biopsy location was at the 
discretion of the treating Gastroenterologist. Biopsies for quantitative real-time 
polymerase chain reaction (qRT-PCR) analysis were stabilised with Allprotect 
(QIAGEN, Venlo, Netherlands) and frozen at -800C pending RNA isolation. 
Biopsies for immunohistochemistry and immunofluorescence confocal 
microscopy analysis were fixed with 10% v/v buffered formalin and paraffin 
embedded. Selection was based on patient pathology reports and only biopsies 
from the descending left colon with active disease features or those diagnosed as 
in IBD remission were chosen for microscopy analysis. 
 
2.3 RNA ISOLATION  
Total RNA was extracted from quiescent and active diseased colon biopsies using 
the RNeasy Plus Mini Kit (QIAGEN, Venlo, Netherlands) as per manufacturer’s 
instructions. Briefly, the Allprotect stabilised tissue was disrupted in 350μL of 
RLT lysing buffer and the tissue was homogenised using a 25-gauge needle 
attached to a 1ml syringe. The homogenised lysate was transferred into an 
RNeasy mini spin column and treated at room temperature with a series of 
buffers to wash the membrane bound RNA. The RNA was then eluted with 20μL 
of nuclease-free water. RNA quality and concentration were determined using the 
Experion automated electrophoresis system (BIO-RAD, Hercules, CA, USA). 
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Samples with a calculated RQI ≥ 8.0 were deemed suitable for qRT-PCR analysis 
or RNA sequencing. 
 
2.4 TRANSCRIPTIONAL PROFILING WITH RNA-SEQUENCING  
RNA samples for sequencing were transported on dry ice to:  
Ramaciotti Centre for Genomics 
Level 1, Biological Sciences Building (D26) 
The University of New South Wales 
NSW 2052 
Telephone: +61 (2) 9385 1658 
Facsimile: +61 (2) 9385 1277 
http://www.ramaciotti.unsw.edu.au 
 
At Ramaciotti, RNA quality, concentration and purity were confirmed using the 
Agilent 2100 Bioanalyzer system (Agilent, Santa Clara, CA, USA).  Library 
preparation was performed using the SureSelect targeted RNA capture kit 
(Integrated Sciences, Sydney, Australia) and libraries were validated on the 
Illumina HiSeq 2000 Sequencer (v2 100bp, pair-end [PE] reads ) (Illumina, San 
Diego, CA, USA) at a concentration of 80Mb. Base-calling was performed off-line 
using Galaxy by Dr Dale Kunde at the University of Tasmania. 
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2.5 COMPLEMENTARY DNA PREPARATION  
RNA was reverse transcribed to cDNA using the iScript cDNA synthesis kit (BIO-
RAD, Hercules, CA, USA) as per manufacturer’s instructions. Briefly, the Experion 
RNA concentration results (ng/μl) determined the volume of RNA needed to 
produce 1μg of cDNA product. For each sample the RNA was combined with 
iScript Supermix, reverse transcriptase and nuclease free water to a final volume 
of 20μL. Samples were incubated at 250C for 5 minutes, 30 minutes at 420C 
followed by 5 minutes at 850C and then held at 40C. Samples were frozen at minus 
800C pending qRT-PCR analysis. 
 
 
2.6 GENE EXPRESSION ANALYSIS 
qRT-PCR was performed on cDNA, at a concentration of 25ng/ml, using TaqMan 
Universal PCR Master mix (Applied Biosystems, Foster City, CA, USA), on-demand 
human gene specific primers (Applied Biosystems, Foster City, CA, USA) (Table 
2-1) and the StepOne Plus PCR system (Applied Biosystems, Foster City, CA, USA).  
A 40 minute fast thermal cycling profile was used for gene expression analysis 
and included  a 2 minute Uracil-N glycosylate (UNG) treatment step at 500C, a 20 
second polymerase activation step at 950C, and 40 cycles of amplification 
(denaturation for 1 second at 950C, annealing and extension for 20 seconds at 
600C). All samples were amplified simultaneously in a one run per designated 
primer/probe assay.  
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Table 2-1: Pre-designed Taqman primer/probes used for gene 
expression analysis 
 
Gene 
symbol 
Gene name 
Catalogue 
identification 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs02758991_g1 
EEF2 Eukaryotic translation elongation factor 2 Hs00157330_m1 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 Hs02800695_m1 
ACTB beta-actin Hs01060665_g1 
IL-1β Interleukin 1, beta Hs01555410_m1 
IL-18 Interleukin 18 (interferon-gamma-inducing-
factor) 
Hs01038788_m1 
NLRP1 NLR family, pyrin domain containing 1 Hs00248187_m1 
NLRP3 NLR family, pyrin domain containing 3 Hs00918082_m1 
NLRP6 NLR family, pyrin domain containing 6 Hs00373246_m1 
AIM2 Absent in melanoma 2 Hs00915710_m1 
SLC7A10 
(ASC) 
Solute carrier family 7 (neutral amino acid 
transporter light chain, asc system), 
member 10 
Hs00219811_m1 
CASP1 Caspase-1, apoptosis related cysteine 
peptidase 
Hs00354836_m1 
NOD1 Nucleotide-binding oligomerisation domain 
containing 1 
Hs00196075_m1 
NOD2 Nucleotide-binding oligomeriszation domain 
containing 2 
Hs00223394_m1 
PPAR-γ Peroxisome proliferator-activated receptor 
gamma 
Hs01115513_m1 
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2.7 IMMUNOHISTOCHEMISTRY ANALYSIS 
Immunohistochemistry was performed on 10% v/v formalin fixed, paraffin 
embedded human tissue.  Sections were deparaffinised and subjected to 0.01 M 
citrate buffer (pH 6.0) antigen retrieval at 1210C for 4 minutes in a decloaking 
chamber. Endogenous peroxidases were quenched by a 5 minute incubation in 
10% H2O2 in methanol. Sections were washed 3 times for 3 minute with 0.1 mol/L 
Tris-buffered saline (TBS). Non-specific binding was blocked by a 20 minute 
incubation with Biocare background Sniper solution (BS966G, Biocare, Concord, 
CA21520, USA). Sections were again washed 3 times for 3 minute with TBS. 
Immunostaining was performed using specific antibodies against  IL-1β (rabbit 
polyclonal, ab9722, Abcam, Cambridge, MA, USA, 1:300), CIAS1/NALP3 [nalpy3-
b] (mouse monoclonal, ab17267, Abcam, Cambridge, MA, USA, 1:300), AIM2 
(rabbit polyclonal, ab93015, Abcam, Cambridge, MA, USA, 1:500), NLRP6 (rabbit 
polyclonal, NBP2-31372, Novus Biological, Littleton, CO, USA, 1:200) and MUC2 
(rabbit polyclonal, H:300: sc15334, Santa Cruz, Dallas, Texas, USA, 1:300), at 
room temperature for 1 hour. Sections were again washed 3 times for 3 minutes 
with TBS. Sections with the anti-CIAS1/NALP3 [nalpy3-b] antibody added were 
incubated with a MACH 1 mouse probe (UP537L10, Biocare, Concord, CA21520, 
USA) at room temperature for 15 minutes. All sections were incubated with a 
horseradish peroxide (HRP)-polymer (MRH53BL10, Biocare, Concord, CA21520, 
USA) for 30 minutes, washed 3 times for 3 minutes with TBS and stained with 
Betazoid DAB chromogen (BDB900B, Biocare, Concord, CA21520, USA) for 5 
minutes. Sections were rinsed with distilled water, counterstained with 
hematoxylin, dehydrated in alcohol/xylene and mounted with distyrene, 
plasticiser and xylene (DPX) mounting media. 
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Slides were examined using an IX71 microscope (Olympus Australia, Melbourne, 
Australia) and images were captured using an attached DP21 microscope camera 
(Olympus Australia, Melbourne, Australia).   
 
2.8 IMMUNOFLUORESCENCE CONFOCAL MICROSCOPY 
Immunofluorescence staining was performed on 10% v/v formalin fixed, paraffin 
embedded human tissue. Sections were deparaffinised and subjected to 0.01 M 
citrate buffer (pH 6.0) antigen retrieval at 1210C for 4 minutes in a decloaking 
chamber.  Non-specific binding was blocked by a 1 hour incubation in blocking 
buffer [0.1 mol/L phosphate-buffered saline (PBS) / 5% normal goat serum 
(ab7481, Abcam, Cambridge, MA, USA) / 0.05% Tween-20] at room temperature 
in the dark.  
Immunofluorescence staining was performed using specific antibodies against 
IL-1β, CIAS1/NALP3 [nalpy3-b], NALP3 [nalpy3-α], NLRP6, AIM2, MUC2 and E-
cadherin (Table 2-2) at room temperature in the dark for 1 hour, or alternatively 
overnight at 40C. Primary antibody was washed 3 times for 5 minutes with 0.1 
mol/L PBS. Sections were incubated for 1 hour in the dark with one or more of 
the following fluorochrome conjugated-secondary antibodies diluted 1:500 in 
[0.1 mol/L PBS / 5% normal goat serum / 0.05% Tween-20]; Goat Anti-Mouse 
(H+L) F(ab’)2  Alexa Fluor®555 Conjugate (#4409, Cell Signalling Technology, 
Danvers, MA, USA),  Goat Anti-Rabbit (H+L) F(ab’)2  Alexa Fluor®555 Conjugate 
(#4413, Cell Signalling Technology, Danvers, MA, USA), Goat Anti-Mouse (H+L) 
F(ab’)2  Alexa Fluor®647 Conjugate (#4410, Cell Signalling Technology, Danvers, 
MA, USA), Goat Anti-Rabbit (H+L) F(ab’)2  Alexa Fluor®647 Conjugate (#4414, 
Cell Signalling Technology, Danvers, MA, USA). Section were then washes 3 times 
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for 5 minutes with PBS. Section were incubated for 10 minutes with 4’ ,6 
diamidino-2-phenylindole Dihydrochloride (DAPI,  (#D1306, ThermoFisher 
Scientific, Waltham, MA, USA) diluted in PBS, washes 3 times for 5 minutes with 
PBS, mounted with ProLong® Gold Antifade (P36930, ThermoFisher Scientific, 
Waltham, MA, USA) and allowed to harden at room temperature for 24 hours 
before imaging. Slides were examined using an FV1200 Laser Scanning Confocal 
Inverted Microscope (Olympus Australia, Melbourne, Australia). Images were 
captured and analysed using a combination of the Olympus IX83 software and the 
off-line FLUOVIEW software. It is important to note that immunofluorescence 
staining on paraffin embedded sections produces images with slightly less 
sensitivity when compared to immunohistochemistry and this can be attributed 
to the inability of immunofluorescence imagery to distinguish between cell 
borders and background tissue. 
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Table 2-2: Primary antibodies used for immunofluorescence confocal 
microscopy 
 
Primary 
Antibody 
Source Manufacturer 
Product 
Number 
Dilution 
IL-1β Rabbit 
polyclonal 
Abcam, 
Cambridge, MA, 
USA 
ab9722 1:100 
CIAS1/NALP3 
[nalpy3-b] 
Mouse 
monoclonal 
Abcam, 
Cambridge, MA, 
USA 
ab17267 1:100 
NALP3 [nalpy3-
α] 
Mouse 
monoclonal 
Abcam, 
Cambridge, MA, 
USA 
ab16097 1:100 
NLRP6 Rabbit 
polyclonal 
Novus Biological, 
Littleton, CO, 
USA 
NBP2-31372 1:200 
AIM2 Rabbit 
polyclonal 
Abcam, 
Cambridge, MA, 
USA 
ab93015 1:100 
MUC2 Rabbit 
polyclonal 
Santa Cruz, 
Dallas, Texas, 
USA 
H-300:sc-
15334 
1:200 
MUC2 Mouse 
monoclonal 
Santa Cruz, 
Dallas, Texas, 
USA 
F-2:sc-515032 1:200 
E-cadherin Mouse 
monoclonal 
Dako North 
America, 
Carpinteria, CA, 
USA 
NCH-38; 
M3612 
1:50 
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2.9 CELL CULTURE EXPERIMENTS       
The human colorectal adenocarcinoma cell line, LS174T was obtained from 
Sigma-Aldrich, Corp. St Louis, MO, USA and cultured in RPMI Medium 1640 
(Gibco, Gaithersburg, MD, USA) supplemented with 10% foetal bovine serum 
(Life Technologies, Carlsbad, CA, USA), glutaMAX™ (Life Technologies, Carlsbad, 
CA, USA), and 1% penicillin/streptomycin (Cellgro, Corning Life Sciences, 
Tewksbury, MA).  
The human colon adenocarcinoma cell line, HT29 was obtained from Sigma-
Aldrich, Corp. St Louis, MO, USA and cultured in McCoy’s 5A Medium 
supplemented with 10% foetal bovine serum (Life Technologies, Carlsbad, CA, 
USA), and 1% penicillin/streptomycin (Cellgro, Corning Life Sciences, 
Tewksbury, MA).  
Both cell lines were maintained in a 370C incubator with 5% CO2 and a relative 
humidity of 95%. Cells between passage 6-10 were washed with Hanks balanced 
salt solution 1x (HBBS) (Life Technologies, Carlsbad, CA, USA),  dissociated using 
TrypLE  Express (Life Technologies, Carlsbad, CA, USA),  and seeded at 
1.2x105/cm2 one day prior to a  6 hour incubation with varying concentration of 
rosiglitazone (chemical abstract service number: 122320-73-4, Sigma-Aldrich 
Corp. St Louis, MO, USA). Cells were washed with HBBS, harvested and RNA was 
extracted using the RNeasy Plus Mini Kit (QIAGEN, Venlo, Netherlands) as per 
manufacturer’s instructions. Briefly, cells were disrupted with 350μL of RLT 
lysing buffer and the homogenised lysate was transferred into an RNeasy mini 
spin column where it was treated with a series of buffers to wash the membrane 
bound RNA. The RNA was then eluted with 50μL of nuclease-free water. RNA 
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quality and concentration was checked using the Experion automated 
electrophoresis system (BIO-RAD, Hercules, CA, USA). 
RNA was reverse transcribed to cDNA using the iScript cDNA synthesis kit (BIO-
RAD, Hercules, CA, USA) as per manufacturer’s instructions. Briefly, the RNA was 
combined with iScript Supermix, reverse transcriptase and nuclease free water 
to a final volume of 20μL. Samples were incubated at 250C for 5 minutes, 30 
minutes at 420C followed by 5 minutes at 850C and then held at 40C. Samples were 
frozen at minus 800C pending qRT-PCR analysis. 
qRT-PCR was performed using TaqMan Universal PCR Master mix (Applied 
Biosystems, Foster City, CA, USA), on-demand human gene specific primers 
(Applied Biosystems, Foster City, CA, USA) (Table 2-1) and the StepOne Plus PCR 
system (Applied Biosystems, Foster City, CA, USA).  
A 40 minute fast thermal cycling profile was used for gene expression analysis 
and included  a 2 minute Uracil-N glycosylate (UNG) treatment step at 500C, a 20 
second polymerase activation step at 950C, and 40 cycles of amplification 
(denaturation for 1 second at 950C, annealing and extension for 20 seconds at 
600C). Experiments were performed in duplicate on 3 separate occasions. 
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2.10 DATA ANALYSIS 
Analysis of qRT-PCR data was performed using a combination of Microsoft Excel 
and GraphPad Prism software (version 7, GraphPad Software Inc. CA. USA). 
Briefly, in Excel the average CT results generated from RT-PCR were grouped 
accordingly and the mean control group CT for the reference gene (Ref.G) and 
genes of interest (G.O.I) were calculated. Sample ∆CT and relative expressions 
were calculated using the following, 
 ΔCT G.O.I = (mean control CT - sample CT), and  
Relative Expression (R.E) G.O.I = (Efficiency G.O.I ᶺ ∆CT G.O.I/Efficiency Ref.G ᶺ 
∆CT Ref.G).  
Gene expression data are presented as scatterplots with horizontal lines 
indicating the median R.E and interquartile ranges and group difference were 
tested using paired t tests of log (10) transformed data. Cell line gene expression 
data are presented as mean +  S.E.M and group differences were assessed using 
one-way analysis of variance (ANOVA).  
Quantitative analysis of immunohistochemistry data was performed using the 
FIJI version (Dec 2009) of ImageJ software 
(http://imagej.nih.gov/ij/downloads.html, Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland, USA), Microsoft Excel and GraphPad 
Prism (version 7, GraphPad Software Inc. CA. USA). Briefly, the mean intensity of 
the DAB signal was measured in FIJI, optical density was calculated in Excel using 
log (maximum intensity/mean intensity), where the maximum intensity of an 8-
bit image = 255. Images containing partial tissue were excluded from analysis 
because of their potential to bias results by reducing the average optical density. 
Group differences and statistical significance were evaluated using one-way 
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analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons in 
GraphPad Prism 7. All data are presented as mean + standard deviation (SD). 
Spatial intensity profiling was performed using FIJI and GraphPad Prism was 
used to graph intensity plots.  
Colocalisation analysis was performed using the Coloc 2 plugin in the Fiji version 
(Dec 2009) of ImageJ software (http://imagej.nih.gov/ij/downloads.html, 
Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, 
USA). To ensure consistency, measurements were only performed on biological 
relevant regions of interest (ROIs) contained within 400X double stained, 
background corrected, confocal images. Briefly in Coloc 2, the Costers method 
was used to determine a threshold point where the two channels of interest 
produced a Pearson’s correlation coefficient of zero. Above this auto threshold 
point all pixels have a correlation greater than zero, while below all pixels have 
none or anti correlated intensities. Using Manders correlation coefficients (M1 
and M2) the co-occurrence of the two channels is described and increases from 0 
to 1 with increasing colocalisation. Pearson’s correlation coefficient (above the 
threshold) was used to describe the correlation of the intensity distribution 
between channels. Quantitative analysis of Manders and Pearson’s correlation 
coefficients was performed on lamina propria ROIs within 400X double stained 
confocal images (n=20). 2D histograms generated in Coloc 2 provided a visual 
inspection of the overall relationship of channel intensities for homologous pixels 
in a selected ROI. Where biological relevant ROIs were void of tissue (for example 
within colonic crypts), spatial intensity profiling was used to assess colocalisation 
of the primary antibodies. 
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Colocalisation data are presented as mean + standard deviation. Statistical 
significance of Pearson’s correlation for the NLRP3/IL-1β double staining was 
evaluated in GraphPad Prism (version 7, GraphPad Software Inc. CA. USA), using 
one-way analysis of variance (ANOVA), followed by Tukey’s multiple 
comparisons test. 
In all presented data the significance threshold was set at p<0.05 and only 
significant data is indicated. 
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CHAPTER 3 GENE EXPRESSION OF INFLAMMASOME 
COMPONENTS IN THE INFLAMMATORY BOWEL DISEASES 
 
3.1 INTRODUCTION 
The gastrointestinal tract is occupied by a wide repertoire of pathogenic and 
symbiotic microorganisms, which interact to shape innate and adaptive immune 
responses. Homeostasis is maintained by an array of germline-encoded pattern 
recognition receptors which detect PAMPs or DAMPs released from pathogen 
insult or cellular stress. Activation of  pattern recognition receptors, such as the 
cytosolic NLRs, CLRs and membrane bound TLRs initiates the signalling 
pathways responsible for downstream pathogen elimination or tissue repair [49-
51].   
In response to DAMPs and PAMPs several members of the NLR receptor family,  
NLRP1, NLRP2, NLRP3, NLRC4, NLRP6, NLRP7 and NLRP12, and two members 
of the pyrin and HIN domain containing (PYHIN) family, absent in melanoma 2 
(AIM2) and the interferon inducible protein (IFI16), also form the structural 
backbone of the innate immune complex known as the inflammasome [48, 68, 
194]. The inflammasome consists of a central platform comprising oligomerised 
receptor molecules, a caspase and often an adaptor protein known as, apoptosis-
associated speck-like protein containing a CARD (ASC). Inflammasomes regulate 
the maturation of the potent proinflammatory cytokines IL-1β and IL-18 through 
the activation of caspase-1.  
Formation of the inflammasome complex is generally regarded as a two-step 
process [86]. Step one, is the priming step and involves receptor signalling to 
induce NF-KB transcription of inflammasome components, proIL-1β and proIL-
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18. Step two, involves a another signal which enhances inflammasome 
oligomerisation, caspase-1 activation, cytokine cleavage, maturation and cellular 
release [97]. 
For many of the inflammasome forming receptors the activating ligands remains 
unknown. The NLRP1 inflammasome is activated by bacterial MDP and lethal 
toxin (LeTx) produced by Bacillus anthracis [84, 195]. The NLRP3 inflammasome 
activates upon exposure to a wide range of whole pathogens, environmental 
irritants and structurally diverse DAMPs and PAMPs [48, 49, 86]. NLRC4 is 
activated by two critical components of pathogenic bacteria, a sequence motif 
found in the basal rod components of the type III (T3SS) and IV (T4SS) bacterial 
secretion systems, and a similar sequence motif found in flagellin, which is a 
component of their flagellum apparatus [114, 115]. Both the cytosolic AIM2 
receptor and the nuclear IFI16 receptor directly bind their activating ligand 
double stranded DNA (dsDNA) via the C terminal HIN200 domain [120-122].  The 
mechanisms that enable AIM2 and IFI16 to respond to viral, bacterial, 
mammalian and synthetic dsDNA while remaining unresponsive to self DNA are 
still unclear [68, 124]. In human macrophages, NLRP7 forms an ASC-dependent 
inflammasome in response to microbial acylated lipopeptides [131]. The signals 
that activate the NLRP6 and NLRP12 inflammasomes are yet to be determined 
[128].  
Important to innate immune defences are NOD1 and NOD2, which belong to the 
NLR family of cytosolic receptors. NOD1 senses intracellular gamma-D-glutamyl-
meso-diaminopimelic acid (iE-DAP) found mainly in Gram-negative bacteria and 
only on some select Gram-positive bacteria, such as Listeria and Bacillus species 
[196-198]. NOD2 has been shown to recognise MDP, a peptidoglycan fragment, 
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found in most Gram-negative and Gram-positive bacteria, and single-stranded 
RNA of viruses [48, 195, 199-202].  
The two main inflammasome producing cytokines, IL-1β and IL-18 are 
structurally similar but differ with respect to biological function. IL-1β is a 
multifunctional cytokine and is involved in generating local and systemic 
responses to injury, infection and inflammation. Clinically, IL-1β has the ability to 
evoke fever and hypotension [203], and control certain central nervous system 
functions such as sleep, appetite and pain [70]. Locally, IL-1β can induce cytokine 
production;  stimulate T cell proliferation, and direct neutrophils to the site of 
injury or infection [50, 204, 205].  
IL-18, is known mainly for its ability to induce IFN-ɣ, however other functions 
include, promoting synthesis of proinflammatory mediators [206], inducing 
endothelial cell migration and cell regeneration [207], and stimulating epithelial 
cell barrier function by the upregulation of adhesion molecules [132, 208]. The 
expression of proIL-1β is induced by the NF-кB transcription factor, and only in 
response to stimulation from TLRs or CLRs, whereas proIL-18 is constitutively 
expressed and its expression is increased after TLR receptor activation [55, 56]. 
PPARs are ligand-activated transcription factors belonging to a superfamily of 
nuclear receptors. PPARs are encoded by distinct genes located on different 
chromosomes and consist of three main members, PPAR-α, PPAR-γ and PPAR-
β/δ. PPAR-γ has been linked to the regulation of intestinal inflammation and is 
highly expressed in the colon [209]. PPAR-γ operates as functional heterodimer 
with the retinoid X receptor (RXR) and together are bound to the promoter 
region of target genes by peroxisome proliferator response elements (PPREs). 
Upon ligand sensing of endogenous metabolites, dietary compounds or synthetic 
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drugs [210] the PPAR-γ/RXR heterodimer undergoes a conformational  change 
that results in the transcriptional activation of target genes [211]. The use of 
transcription mapping has revealed potential PPAR-γ/RXR binding sites in 
regions upstream of the NLRP6 promotor, which are conserved across human, 
rat and mouse suggesting possible transcription control of NLRP6 by PPAR-γ 
[212].  
Aberrant signalling of the inflammasome complex is hypothesised to be a key 
initiating event in the development of ulcerative colitis and Crohn’s disease.  The 
aim of this study was therefore to investigate the mRNA expression of 
inflammasome components in quiescent and active UC and CD using qRT-PCR 
and RNA Sequencing.  
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3.2 RESULTS 
3.2.1 STUDY PARTICIPANT DEMOGRAPHICS 
IBD patients comprised 65 out of the total 85 participants, and of these 35 were 
females and 30 were males. The mean age of IBD patients providing paired 
biopsies was slightly younger for the ileal (41 + 16) and colonic (46 + 15) CD 
group than the UC group (50 + 18). Within the UC categories, patients presenting 
with colonic disease in its entirety were in general younger than the UC patients 
in remission or those with limited disease (Table 3-1). While in CD, the young age 
of remission patients could possibly be a reflection of close monitoring of newly 
diagnosed patients.  
 
3.2.2 CLINICAL CHARACTERISTICS OF STUDY PARTICIPANTS 
Forty-four UC patients participated in this study. At the time of biopsy collection, 
27 were taking prescription medication to control their disease while 17 patients 
were untreated (Table 3-2). Eighty one percent (22/27) of treated UC patients 
were prescribed 5-aminosalicylates and 50% (11/22) of those taking 5-
aminosalicylates were also prescribed corticosteroids. Approximately 55% of UC 
participants had coexisting medical conditions requiring prescription 
medication, 16% (7/44) experienced depression/anxiety, 11% had arthritis 
(5/44) and similarly 11% (5/44) had asthma. Reflux was a common complaint 
requiring prescription medication but this was thought to be a side effect of drug 
therapy or a reflection of lifestyle factors. 
Twenty-one CD patients participated in this study, of these 76% (16/21) were 
being treated and 5 patients (24%) were not being treated at the time of biopsy 
collection (Table 3-3). While 5-aminosalicylates (29%, 6/21) and corticosteroids 
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(10%, 2/21) were often prescribed for CD, a larger proportion of CD patients 
were being treated with biologic agents (19%, 4/21) and immunomodulators 
(29%, 6/21). Forty-three percent (9/21) of CD participants experienced 
concurrent medical conditions with depression and anxiety disorders (24%, 
5/21) being more frequent. Interestingly, there was a higher proportion of 
smokers in the CD group (24%, 5/21) when compared to the UC group (5%, 
2/44).  
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Table 3-1: Demographic details of study participants 
 
 
 
 
 
  
Patient category Number of 
patients 
Age (years) Gender Disease 
duration 
Control patients 20 57 ± 14 11F, 9M - 
Paired UC* 
 
30 50 ± 18  16F, 14M 11 ± 12 
Quiescent UC only 10 49 + 11 6F, 4M 15 + 11 
Active UC only 4 39 ± 21 2F, 2M 11 ± 13 
Paired ileal CD* 6 41 + 16 2F, 4M 12 + 8 
Active ileal CD only 1 28 1M 15 
Paired Colonic CD* 9 46 + 15 4F, 5M 8 + 4 
Active colonic CD only 1 46 1F 11 
Quiescent CD (includes 
ileal CD and colonic CD) 
only 
4 20 + 7 3F, 1M 9 + 14 
All data are shown as mean ± standard deviation. The age of the subject during 
the biopsy is shown in years. Gender is given as F, females and M, males. The 
disease duration in years at the time of biopsy is shown for each group as the 
mean value ± standard deviation. The average onset of disease can be 
calculated by subtracting the disease duration from the average age of the 
patient. 
*Patients had biopsies taken from quiescent disease and active disease regions 
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Table 3-2: Clinical characteristics of ulcerative colitis patients 
Variable 
Patients with 
both  active and 
quiescent 
disease  
Patients 
in 
remission 
Patients 
with active 
disease only 
Patients, n 30 10 4 
Smoker, n (%) 1 (3) 1 (10) 0 
Disease extent*    
Proctitis only 7 (23) - - 
Proctosigmoiditis 14 (47) - - 
Left-sided colitis 8 (27) - - 
Pancolitis 1 (3) - 4 (100) 
Current medication for UC    
Untreated 12 (40) 3 (30) 2 (50) 
Aminosalicylates (5-ASA) 16 (53) 5 (50) 1 (25) 
Corticosteroids 6 (20) 3 (30) 2 (50) 
Immunomodulator therapy 4 (13) - - 
Topical therapy 0 - - 
Biologic therapy 0 - - 
Antibiotics/probiotics/            
vitamin supplements 
6 1 - 
Concurrent  medical conditions    
none 14 (47) 4 (40) 2 (50) 
Asthma 5 - - 
Depression/ anxiety 5 - 2 
Diabetes 1 1 - 
High blood pressure 4 1 1 
High cholesterol 3 1 - 
Arthritis 2 2 1 
Thyroid condition 1 - - 
Reflux 4 1 - 
Gout 1 1 - 
Age and disease duration data are shown as mean value + standard deviation. 
Other data indicates the number of patients. Group percentages are shown in 
brackets. 
*Disease extent: 
Proctitis: Disease only in the rectum 
Proctosigmoiditis: Disease in the rectum and sigmoid colon 
Left-sided colitis: Limited or distal colitis. Disease in left side of the colon. 
Pancolitis: Disease in the entire colon. 
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Table 3-3: Clinical characteristics of Crohn's disease patients 
Variable 
Patients with 
both  active and 
quiescent 
disease  
Patients in 
remission 
Patients 
with active 
disease only 
Patients, n 15 4 2 
Smoker, n (%) 4 (27) 1 (25) 0 
Disease extent*    
Ileum only 4 (27) - 1 
Ileum and colon 2 (13) - - 
Colon only 9 (60) - 1 
Extra-intestinal manifestations 
(eg ileocaecal/perianal/proctitis)  
4 (27) - - 
Previous surgical resection 4 (27) 1 - 
Current Medication for CD    
Untreated 4 (27) 1 (25) - 
Aminosalicylates (5-ASA) 5 (33) 1 - 
Corticosteroids 2 (13) - - 
Immunomodulator therapy 6 (40) 1 1 
Topical therapy - - - 
Biologic therapy 2 (13) 1 1 
Antibiotics/probiotics/            
vitamin supplements 
- - - 
Concurrent  medical conditions    
none 9 (60) 3 (75) 0 
Asthma 1 -  
Depression/anxiety 2 1 2 
Heart disease 1 - - 
Arthritis 1 - - 
Reflux 1 - - 
Iron deficiency 1 - - 
Ankylosing spondylitis 1 - - 
Age and disease duration data are shown as mean value + standard deviation. 
Other data indicates the number of patients. Group percentages are shown in 
brackets. 
*Disease extent: Extra-intestinal manifestations (eg ileocaecal/perianal/ 
proctitis) included as a separate section but can co-exist with colonic and ileum 
manifestations. 
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3.2.3 EXPRESSION OF TARGETED INFLAMMASOME GENES IN IBD  
Quantitative RT-PCR and RNA sequencing were used to determine the expression 
of inflammasome related genes in colonic biopsies from quiescent and active 
disease regions. Justification for the use of EEF2 as the housekeeping gene for 
normalisation is presented in Appendix 5.  
Overall, the expression of the inflammasome forming receptors, AIM2, NLRP1, 
NLRP3 and NLRP6 were found to increase with disease activity in both UC and 
CD (Table 3-4). The appearance of two distinct NLRP6 expression populations in 
the active CD population prompted comparison with disease phenotypes. In 
patients with disease involving the terminal ileum (Montreal classification; L1, 
terminal ileum involvement and L3, ileocolonic involvement) the median relative 
expression of NLRP6 increased 131-fold (p<0.001) with active disease (Table 3-
4). In contrast, a 3.9-fold (p=0.03) increase in NLRP6 expression was observed 
in colonic CD patients (Montreal classification; L2, colonic disease). The 
expression of NLRP6 in active ileal CD was notably increased when compared to 
active colonic disease (p<0.001) (Figure 3-1D).  
Given the overrepresentation of transcription factor binding sites for PPAR-γ 
upstream of the NLRP6 transcription start site [212] the expression profile of 
PPAR-γ was examined for evidence of possible transcriptional regulation of 
NLRP6. The expression of PPAR-γ decreased with disease activity for both UC and 
CD with the least expression evident in active ileal CD (0.2-fold reduction, 
p=0.002) (Table 3-4, Figure 3-1K). 
The expression of AIM2 was higher in active ileal CD (16.4-fold, p=0.009) than 
active colonic CD (10.7-fold, p=0.014) but comparable to active UC (10.2-fold, 
p<0.001) (Figure 3-1A). While the increased expression of NLRP1 and NLRP3 
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was unremarkable when examined across active disease phenotypes (Figures 3-
1B and 3-1C).  
Consistent with inflammasome activation the expression of IL-1β, CASP1 and ASC 
increased with disease activity in both UC and ileal CD (Figures 3-1E, 3-1G and 3-
1H). Interestingly, the expression of IL-18 remained constant in UC (p=0.10), 
ileal (p=0.24) and colonic CD (p=0.22) despite the increase in disease activity 
and demonstrated inflammasome activation (Figure 3-1F). Upregulation of 
inflammasome forming components in ileal and colonic CD were confirmed by 
RNA-sequencing (Figures 3-2 and 3-3). 
The expression of the NOD bacterial sensor, NOD2 increased with disease activity 
for both UC (p<0.001) and CD (ileal, p=0.009; colonic, p<0.001) however NOD1 
only increased in UC (p<0.001) (Figures 3-1I and 3-1J). 
 
3.2.4 CORRELATION OF INFLAMMASOME COMPONENTS  IN ACTIVE 
DISEASE 
NLRP3 showed the strongest correlation with IL-1β for both UC (Rs=0.78, 
p<0.01) and CD (Rs=0.96, p<0.01) (Figure 3-4). The correlation of IL-1β to 
NLRP1 and AIM2 was weaker in both UC (NLRP1, Rs=0.48, <0.01; AIM2, 
Rs=0.47, p<0.01) and CD (NLRP1, Rs=0.65, p<0.01; AIM2, Rs=0.75, p<0.01). 
Interestingly, there was no correlation between NLRP6 and IL-1β for both UC 
(Rs=0.32, p=0.09) and CD (Rs=0.12, p=0.65). IL-18 showed the strong 
correlation to CASP1 in both UC (0.79, p<0.01) and CD (Rs=0.73, p<0.01). 
Noteworthy the correlation of AIM2 to NLRP3 was stronger in active CD 
(Rs=0.83, p<0.01) than active UC (Rs=0.65, p<0.01) (Table 3-5). 
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Table 3-4: Expression of targeted inflammasome related genes in IBD 
 
Target 
Gene 
Disease 
phenotype 
Quiescent disease Active disease 
P 
Median 
R.E 
IQR 
Median 
R.E 
IQR 
AIM2 
Ileal CD^ 0.9 0.6 – 4.0 16.4 4.9 – 57.9 0.009 
Colonic 
CD+ 
1.8 0.7 – 4.9 10.7 5.2 – 14.3 0.014 
UC# 1.0 0.7 – 2.3 10.2 7.1 – 14.8 <0.001 
NLRP1 
Ileal CD^ 2.0 0.7 – 2.4 4.2 2.7 – 6.3 0.002 
Colonic 
CD+ 
1.0 0.6 – 3.0 5.6 3.3 – 6.4 0.031 
UC# 1.4 1.0 – 1.6 4.9 3.3 – 6.3 <0.001 
NLRP3 
Ileal CD^ 1.2 0.8 – 1.8 5.6 2.5 – 16.3 0.009 
Colonic 
CD+ 
2.7 1.1 – 3.1 8.5 2.6 – 17.3 0.024 
UC# 1.5 1.0 – 2.3 3.7 2.5 - 5.7 <0.001 
NLRP6 
Ileal CD^ 1.4 0.7 – 1.7 131.0 109.1 – 260.4 <0.001 
Colonic 
CD+ 
1.7 0.6 – 2.9 3.9 2.9 – 5.6 0.03 
UC# 1.3 0.9 – 2.1 1.8 1.2 – 3.0 0.01 
IL-1β 
Ileal CD^ 3.5 1.7 – 4.8 83.8 16.1 – 265.1 0.002 
Colonic 
CD+ 
4.1 1.5 – 19.2 63.5 9.4 – 309.4 0.02 
UC# 2.2 0.8 – 5.9 28.1 13.2 – 78.7 <0.001 
IL-18 
Ileal CD^ 1.7 0.8 – 4.1 1.2 0.6 – 2.5 0.24 
Colonic 
CD+ 
1.1 0.7 – 3.2 2.3 1.3 – 4.9 0.22 
UC# 1.0 0.6 – 1.8 1.7 0.8 – 3.4 0.10 
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Target 
gene 
Disease 
phenotype 
Quiescent disease Active disease 
P 
Median 
R.E 
IQR 
Median 
R.E 
IQR 
CASP1 
Ileal CD^ 1.8 0.7 – 4.3 10.0 4.0 – 20.7 0.041 
Colonic 
CD+ 
2.2 1.1 – 5.2 6.9 3.4 – 8.3 0.077 
UC# 1.3 0.8 – 2.3 5.1 2.9 – 9.3 <0.001 
ASC 
Ileal CD^ 1.7 0.8 – 4.0 26.8 2.5 – 147.2 0.026 
Colonic 
CD+ 
0.7 0.5 – 1.9 2.7 1.3 – 7.2 0.161 
UC# 1.0 0.5 – 1.7 4.8 2.3 – 9.2 <0.001 
NOD1 
Ileal CD^ 1.4 0.9 – 2.1 1.3 0.9 – 1.6 0.699 
Colonic 
CD+ 
1.1 0.7 – 1.8 1.5 1.3 – 1.7 0.190 
UC# 1.1 0.9 – 1.4 1.6 1.5 – 1.9 <0.001 
NOD2 
Ileal CD^ 2.0 1.4 – 4.9 6.9 5.6 – 10.1 0.009 
Colonic 
CD+ 
2.5 1.8 – 3.4 5.8 3.9 – 19.3 <0.001 
UC# 1.5 0.9 – 2.1 8.0 4.6 – 10.4 <0.001 
PPAR-γ 
Ileal CD^ 1.2 0.8 – 2.7 0.2 0.2 – 0.3 0.002 
Colonic 
CD+ 
0.9 0.6 – 1.4 0.6 0.3 – 0.9 0.113 
UC# 0.9 0.8 – 1.3 0.5 0.3 – 0.6 <0.001 
Quantitative RT-PCR was used to determine the expression of inflammasome 
related genes in IBD. Median Relative Expression (R.E) and interquartile 
ranges (IQR) are relative to the control group and normalised to the 
housekeeping gene EEF2.  Group differences were tested using Mann-Whitney 
test of log (10) transformed data. The significance threshold was p<0.05. 
# Column statistics for UC patients; quiescent disease n=40, active disease 
n=34; group difference for UC patients, n=30 
^ Column statistics for ileal CD include 6 paired biopsy patients and one 
patient with active disease that was a known ileal CD patient 
+ Column statistics for colonic CD = 9 patients  
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Figure 3-1: Gene expression of inflammasome related genes in paired 
biopsies from quiescent CD (qCD), active CD (aCD), quiescent UC 
(qUC) and active UC (aUC).  
The mRNA expression of  A) AIM2, B) NLRP1, C) NLRP3, D) NLRP6, E) IL-1β, F) 
IL-18, G) CASP1, H) ASC, I) NOD1, J) NOD2, K) PPAR-γ was compared to a healthy 
control group and normalised to the housekeeping gene, EEF2. Individual patient 
results are shown as dots. Horizontal lines indicate the median relative 
expression (R.E) and error bars represent the interquartile ranges. Group 
differences were tested using Mann-Whitney test of log (10) transformed data. 
The significance threshold was p<0.05. 
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Figure 3-2: Targeted RNA-sequencing analysis of ileal CD colon 
biopsies during active disease. 
Gene expression results (n=4) are expressed as Log 2 (fold change), normalised 
to housekeeping genes and relative to a normal control group (n=4) which is 
indicated by the dotted vertical line. Upregulated genes are shown as red, 
downregulated genes are shown as blue. The significance threshold was p<0.05. 
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Figure 3-3: Targeted RNA-sequencing analysis of colonic CD colon 
biopsies during active disease. 
Gene expression results (n=4) are expressed as Log 2 (fold change), normalised 
to housekeeping genes and relative to a normal control group (n=4) which is 
indicated by the dotted vertical line. Upregulated genes are shown as red, 
downregulated genes are shown as blue. The significance threshold was p<0.05. 
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Figure 3-4: Correlation of NLRP3 to IL-1β in active UC and active CD  
A) Correlation of NLRP3 and IL-1β relative gene expression in active UC B) 
Correlation of NLRP3 and IL-1β relative gene expression in active CD.   
Spearman’s rank correlation coefficient (Rs) was used to assess the level of 
association and p<0.05 was considered significant. 
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3.3 DISCUSSION 
This study demonstrated the mRNA upregulation of inflammasome forming 
receptors, inflammasome components and bacterial sensors in active disease 
which suggests activation of the inflammasome complex. Furthermore, it 
provided evidence for the upregulation of NLRP6 (131-fold) in active ileal CD 
which was not observed in active colonic CD or active UC. 
The inflammasome complex is the key regulator of IL-1β production. The 
demonstrated increase in IL-1β gene expression in both active UC and CD is well 
established and consistent with previous research in human derived material 
[213-217]. The concomitant expression of IL-1β and the inflammasome receptor 
proteins, AIM2, NLRP1, NLRP3 and NLRP6 prevents comparison of the individual 
inflammasome to the overall production of IL-1β. NLRP3 did however correlate 
the strongest with IL-1β in active UC and CD. 
The high expression of ASC in ileal CD is likely to be a reflection of the high NLRP6 
and AIM2 inflammasome activation in this disease group. Previous work in 
human cell lines have indicated upregulation of ASC with inflammasome 
activation [218, 219]. The increased CASP1 expression in active UC and CD is well 
established and consistent with previous studies in human derived material [214, 
220].  
NLRP6 in ileal CD was shown to increase 131-fold with disease activity. In a 
paediatric IBD population from Canada the expression of NLRP6 was found to be 
low and there was no significant variation between UC and CD [221]. Taken 
together the NLRP6 discrepancy could be related to age, genetic variability or 
lifestyle factors and warrants further investigation.  
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The expression of IL-18 remain unchanged in both UC and CD despite increased 
disease activity. Previously, increased serum levels of IL-18 [222] and IL-18 
transcript levels (by semi-quantitative PCR) [206, 223, 224] have been associated 
with CD.  
In the murine system, discrepancies exist regarding the association of NLRP6 to 
the production of IL-18. Firstly, Nlrp6 deficiency has been associated with low 
levels of IL-18 [129, 186] and the induction of intestinal IL-18 has been shown to 
be NLRP6 dependent [225]. In disagreement Normand et al [226] reported no 
NLRP6-dependent changes in the transcript abundance of IL-18 in tumoral and 
non-tumoral biopsies procured from Nlrp6+/+ and Nlrp6-/- mice. In agreement 
with Normand et al [226], this study reports no change in the expression of IL-18 
despite fluctuating NLRP6 expression, suggesting IL-18 expression is not NLRP6 
dependent.  
The expression of PPAR-γ was found to be reduced in both active UC and active 
CD, notably in ileal CD. Previously, the expression of PPAR-γ has been reported 
as reduced in active UC and comparable to normal colon in active CD [227, 228]. 
The notable reduction in active ileal CD suggests possible negative 
transcriptional control of NLRP6 by PPAR-γ and warrants further investigation.   
The demonstrated increase of NOD2 in active UC is well established and 
consistent with previous research in cell lines and human derived material [229-
232]. Likewise, constitutive expression of NOD1 has been demonstrated in cell 
lines and is consistent with the uniform expression observed in CD for the current 
study [233, 234]. The difference in expression levels of NOD1 and NOD2 in UC 
and CD are in part a reflection of their function. NOD2 is a general bacterial sensor 
and activates upon exposure to most Gram-negative and Gram-positive bacteria 
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while NOD1 only senses Gram-negative bacteria but can act as a backup sensor 
for Gram-negative bacteria that have evaded the TLR system [213, 234]. NOD1 
and NOD2 have also been implicated in bacterial clearance pathways 
downstream of inflammasome activation, such as ROS, reactive nitrogen species 
(RNS) and autophagy pathways [235]. NOD2 increases the production of 
antimicrobial α-defensins from paneth cells, and both NOD1 and NOD2 enhance 
autophagy by co-localising with ATG16LI at the plasma membrane to assist in 
autophagosome formation [236-238]. Therefore, considering the ways in which 
NOD1 and NOD2 enhance bacterial killing it is possible that the upregulation of 
NOD1 and NOD2 in UC and upregulation of NOD2 in active CD is an innate 
immune response to an increased bacterial burden. The absence of upregulation 
of NOD1 in active CD is a reflection of the gut microbiota composition.  
In conclusion, results of this study suggest activation of multiple inflammasome 
complexes in active UC and CD. The identification of NLRP6 as a disease specific 
marker for ileal CD will be the focus of work presented in Chapter 6.  
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CHAPTER 4 COLONIC LOCALISATION AND 
INTRAEPITHELIAL LYMPHOCYTE EXPRESSION OF AIM2   
 
4.1 INTRODUCTION 
Microbial DNA is highly immunostimulatory and can trigger multiple pattern 
recognition receptors and initiate responses via several innate immune pathways 
[239, 240]. The presence of unmethylated CpG DNA (found in prokaryotic DNA 
but suppressed in mammalian DNA [241]) in endo-lysosomal compartments 
activates the membrane bound TLR9 receptor, initiating the downstream 
activation of inflammatory cytokines such as TNF-α, IL-1, IL-6 and IL-18 via NF-
kB transcription and MAPK pathways [51, 242]. 
Prokaryotic, viral and non-microbial DNA when internalised or delivered into the 
cytoplasm of cells triggers TLR independent sensing by cytoplasmic DNA sensors, 
such as absent in melanoma 2 (AIM2). AIM2 is a member of the pyrin and 
hematopoitic interferon-inducible nuclear proteins (HIN) (PYHIN) receptor 
family for which there are 4 human members and 11 confirmed mouse members 
[79].  The structure of AIM2 consists of an N-terminal pyrin domain (PYD) 
domain attached to a hemopoietic interferon-inducible nuclear protein (HIN-
200-C) domain at the C-terminal [80]. The PYD domain forms homotypic 
interactions with other PYD-containing proteins while the HIN-C domain directly 
binds to dsDNA of at least 80 base pairs in length, irrespective of its sequence 
composition [120-122]. Binding occurs at multiple sites along the dsDNA and is 
through electrostatic attractions between the positively charged HIN domain 
residues and the dsDNA sugar phosphate backbone. In the absence of DNA, the 
HIN-C domain interacts with the PYD domain to provide autoinhibition [123].  
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The presence of cytoplasmic DNA triggers several AIM2 dependent innate 
immune pathways that result in the production of inflammatory cytokines, anti-
viral type I interferons (IFNα/β) [240] and cell death via pyroptotic caspase-1 
[243] and the apoptotic executioner caspase-3 [244]. The AIM2 inflammasome 
pathway activates caspase-1 in an ASC-dependent manner, which enhances the 
maturation of inflammatory cytokines, IL-1β and IL-18 [120, 121]. Aberrant 
signaling of the inflammasome complex is thought to be a contributing factor in 
the development of gastrointestinal disease. 
In mouse models utilising DSS and azoxymethane, AIM2 protects the colonic 
epithelium against tumorigenesis [245]. Furthermore, mutations in the AIM2 
gene have been reported in human colorectal cancer with reduced expression of 
AIM2 in colorectal cancer being associated with a poor prognosis for the patient 
[246, 247]. Similarly, prostate cancer cells also exhibit reduced AIM2 expression 
[248]. Interestingly, the overexpression of AIM2 protein in human cancer cell 
lines has been shown to  inhibit cell proliferation and cancer progression [249]. 
AIM2 is yet to be linked to any inherited  autoinflammatory diseases and no gain 
of function mutations have been identified within the AIM2 gene [250]. AIM2 
does however fall within the susceptibility loci for systemic lupus erythematous 
and research to determine the contribution of AIM2 to disease development is 
ongoing [251-253]. 
It was hypothesised that AIM2 provides cytoplasmic surveillance against foreign 
DNA and contributes to innate immune defences in the gut by directing 
downstream inflammatory pathways via the inflammasome complex. In Chapter 
3, gene expression data demonstrated the upregulation of AIM2 in active disease. 
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Following on from these results the aim of Chapter 4 was to examine the cellular 
localisation of AIM2 in quiescent and active disease. 
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4.2 RESULTS 
4.2.1 AIM2 ANTIBODY OPTIMISATION 
In order to investigate the localisation of AIM2 in colon tissue it was first 
necessary to establish the efficiency of the AIM2 antibody (ab93015, Abcam, 
Cambridge, MA, USA) in human control tissue. Using normal human tonsil tissue 
positive nuclear staining was observed in the germinal centre and non-germinal 
centre cells with scattered AIM2 expression evident in the stratified squamous 
epithelium (Figures 4-1 and 4-2). This is consistent with the Abcam product 
information sheet (ab93015, Abcam, Cambridge, MA, USA) (Appendix 6) which 
demonstrated positive nuclear staining in formalin fixed paraffin embedded 
human foetal tonsil using immunohistochemistry. 
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Figure 4-1:  (previous page) Localisation of AIM2 in normal human 
tonsil tissue as analysed by immunohistochemistry.  
Tissue was paraffin embedded, cut into 5 μm sections and incubated with the 
AIM2 antibody (ab93015, Abcam, Cambridge, MA, USA) at a dilution of 1:500. 
Scale bars represent 200 μm for 100X and 50 μm for 400X magnification. 
 
 
 
 
 
Figure 4-2: Representative immunofluorescence confocal images of 
AIM2 localisation in normal human tonsil tissue 
All sections were paraffin embedded, cut into 5 μm sections, incubated with the 
AIM2 antibody (ab93015, Abcam, Cambridge, MA, USA, 1:500 dilution) and 
visualised using Alexa Fluor®647 conjugated goat anti-rabbit IgG (red). Nuclei 
were stained with 4’ ,6 diamidino-2-phenylindole (DAPI, blue). Scale bars 
represent 100 μm for both the 100X and 400X magnification. 
  
AIM2                100X 400X 
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4.2.2 COLONIC LOCALISATION OF AIM2 
Immunohistochemistry and immunofluorescence confocal microscopy were 
used to determine the cellular localisation of AIM2 in active and remission IBD 
(Figures 4-3 and 4-4). In the normal colon, AIM2 was mainly expressed in the 
epithelial cell layer at the base of the intestinal crypt with expression 
disseminated along the crypt length. 
In active UC and active CD (ileal and colonic) high AIM2 expression was evident 
along the entire length of intestinal crypt with intense AIM2 staining present in 
immune cells of the lamina propria. The expression of AIM2 in UC remission was 
slightly reduced. 
In all IBD and normal colon biopsies prominent AIM2 expression was observed 
in the intraepithelial lymphocytes lining the intestinal crypts (Figure 4-4, green 
arrow) which is consistent with work by Vanhove et al [254]. Interestingly, 
strong AIM2 expression was often observed deep within the crypt and extending 
into the lumen (Figure 4-4, white arrow). 
Quantitatively, AIM2 immunohistochemistry staining was higher in active 
disease (normal vs active UC, p<0.001; normal vs active ileal CD, p<0.001; 
normal vs active colonic CD, p=0.003) than in the normal colon and there was a 
reduction in AIM2 expression with UC remission (UC active vs quiescent UC, 
p<0.001). Furthermore, in CD there was no reduction in AIM2 expression with 
disease remission (Figure 4-5). 
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Figure 4-3: Representative immunohistochemistry images of AIM2 
expression in  normal colon, active UC, remission UC, active ileal and 
colonic CD and remission CD.  
All biopsies were taken from the left colon (unless stated as ileum biopsy), 
paraffin embedded, cut into 5 μm sections and incubated with AIM2 (ab93015, 
Abcam Cambridge, MA, USA) at a dilution of 1:500. Scale bars represent 200 μm 
for 100X and 50 μm for 400X magnification. 
 
Figure 4-4 (next page): Representative immunofluorescence confocal 
images of AIM2 localisation in normal colon, active UC, active ileal and 
colonic CD.  
All biopsies were taken from the left colon, paraffin embedded, cut into 5 μm 
sections, incubated with AIM2 (ab93015, Abcam, Cambridge, MA, USA, 1:100 
dilution) and visualised using Alexa Fluor®647 conjugated goat anti-rabbit IgG 
(red). Nuclei were stained with 4’ ,6 diamidino-2-phenylindole (DAPI, blue). 
Green arrows indicate AIM2 positive intraepithelial lymphocyte, white arrow 
indicates extension of AIM2 expression into crypt lumen. Scale bars represent 
100 μm for both the 100X and 400X magnification. 
Active 
colonic CD 
  
Remission 
CD 
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Figure 4-5: Quantification of AIM2 immunohistochemistry staining in 
biopsy sections from normal and IBD patients 
 Quantitative analysis of AIM2 expression in sections from normal colon (total 
number of images analysed=12), active UC (n=104), remission UC (Rem. UC, 
n=30), active ileal CD (n=24), active colonic CD (n=16) and remission CD (Rem. 
CD, n=40). Paraffin embedded left colon mucosal biopsies were analysed by 
immunohistochemistry and the optical intensity of DAB staining due to AIM2 was 
determined using FIJI software. All data are presented as mean + standard 
deviation. Statistical significance was evaluated using Dunn’s multiple 
comparison one-way analysis of variance (ANOVA). The significance threshold 
was p<0.05. 
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4.3 DISCUSSION 
This study describes the localisation of AIM2 expression in quiescent and active 
IBD. Abundant AIM2 expression was found in the epithelial cell layer and lamina 
propria immune cells of colonic and ileum biopsies from active UC and CD. In 
contrast, the expression of AIM2 in normal colon was localised to the crypt base 
and disseminated along the length of the colon.  
The epithelia cell layer is often the first point of contact for the pathogens that 
cause disease. Intraepithelial lymphocytes are geared to provide immediate and 
heightened immune protection to avoid initial entry and spreading of pathogens 
[255]. The prominent and consistent expression of AIM2 in the intraepithelial 
lymphocyte cells and protrusion into the lumen suggests AIM2 is a key 
participant in innate defences during active disease. AIM2 plays an important role 
in the recognition of viruses and bacteria by the detection of cytosolic dsDNA. 
Aim2 deficient mice have demonstrated a critical role for AIM2  in the detection 
of Fransicella tularenis, vaccinia virus, murine cytomegalovirus, Listeria 
monocytogenes, Streptococcus pneumonia, species of Mycobacterium, Legionella 
pneumophilia and Staphylococcus aureus [120, 125-127, 256].    
AIM2 expression can be rapidly induced by using treatments that  promote type 
1 interferon (IFN) signaling [250], and previous work  has detected basal AIM2 
expression in the small intestine, sigmoid colon, rectum, spleen, tonsil, peripheral 
white blood cells, keratinocytes and testis [80, 249, 257, 258].  
The diversity of the gut microbiome tends to be individual-specific and is 
influenced by lifestyle factors like diet, medication, age and illness [259]. In the 
normal human gut a dynamic and complex symbiosis exist between the 
potentially pathogenic bacteria and the “friendly” bugs such as the dominant 
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Gram-positive Lactobacilli and Bifidobacteria [260]. Lactobacilli and 
Bifidobacteria compete with pathogens like Bacteriodetes, Clostridium, 
Staphylococcus, and Enterobacter for cell adhesion, hence preventing contact 
with the intestinal epithelium [261, 262].  
In active UC, increased bacterial numbers and alterations in microbial 
populations are a common finding, and disease remission induces populations 
comparable to normal gut populations. In contrast, the microbial populations in 
CD are not altered by disease remission [191]. Interestingly, quantitatively 
analysis of AIM2 expression in active CD and remission CD were comparable, 
suggesting the expression of AIM2 is dependent on the local microbial 
population. 
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CHAPTER 5 COLONIC LOCALISATION AND SPATIAL 
INTENSITY RELATIONSHIP OF NLRP3 AND INTERLEUKIN 
(IL)-1BETA 
 
5.1 INTRODUCTION 
An effective host defence and subsequent modulation of the adaptive immune 
response relies on the induction, production and release of proinflammatory 
cytokines. One member of the IL-1 family of cytokines, IL-1β is highly 
inflammatory [263] and classified as a multifunctional cytokine. IL-1β 
participates in local and systemic responses to injury, infection and inflammation. 
Clinically, IL-1β has the ability to evoke fever and hypotension [203], and control 
certain central nervous system functions such as sleep, pain and appetite [70]. 
Locally, IL-1β can induce cytokine production,  enhance T cell activation and 
antigen recognition, and direct neutrophils to the site of injury or infection [50, 
204, 205].  
IL-1β is produced as an inactive 31kDa proIL-1β protein in response to TLR 
activation and enzymatic cleavage is required to generate a bioactive 17kDa IL-
1β fragment [132]. The synthesis of a precursor cytokine requiring activation by 
proteases prevents aberrant secretion of IL-1β.  
Several inflammasomes such as, NLRP1, NLRP3, NLRC4, NLRP6, NLRP7, NLRP12, 
AIM2 and IFI16 have been described for the canonical activation of caspase-1 and 
maturation of IL-1β [48]. Inflammasome activation is regarded as a two-step 
process. Transcription and translation of inflammasome components precedes 
the ligand activation step, which culminates in the assembly of the inflammasome 
platform and the maturation of IL-1β [95, 96]. Formation of the NLRP3 
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inflammasome complex occurs in response to a wide range of microbial, 
environmental and sterile ligands [48, 49]. While the exact mechanisms of ligand 
activation are yet to be determined it is generally accepted that assembly of the 
NLRP3 inflammasome occurs in response to host derived factors altered by these 
agents. The indirect mechanisms include K+ efflux [87], phagolysosmal 
destabilisation and release of cathepsins [89], the release of mitochondrial DNA 
or the mitochondrial phospholipid cardiolipin [90-92], translocation to the 
mitochondria [88, 93, 94] or the presence of mROS [88].  
In addition to inflammasome-dependent production of IL-1β, several cell specific 
inflammasome-independent processes exist for the activation of IL-1β. IL-1β is a 
primary product of blood monocytes, tissue macrophages, neutrophils, dendritic 
cells and to a lesser extent, B lymphocytes and Natural Killer cells [264]. In blood 
monocytes, caspase-1 is constitutively expressed and the production of active IL-
1β occurs via transcriptional control of proIL-1β. This mechanism is thought to 
aid host defences by reducing immune response time [60].   
The zinc-dependent metalloproteinases, meprin A and meprin α are highly 
expressed at the brush-border membranes of the kidney and intestine and are 
capable of generating biologically active IL-1β [265]. During acute inflammation, 
neutrophil and macrophage derived serine proteases, proteinase 3, elastase and 
cathepsin G can process proIL-1β to biologically active IL-1β [60-63].  Indeed, 
microbes such as Candida albicans and Staphylococcus spp. can themselves 
produces proteases, which possess the ability to cleave IL-1β [266, 267].  
Taken altogether, IL-1β is a highly inflammatory cytokine and numerous 
mechanisms control the production and activity of IL-1β. In the gut it is 
hypothesised that the NLRP3 inflammasome directs downstream innate immune 
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defences by regulating the maturation of the IL-1β cytokine. In Chapter 3, gene 
expression data demonstrated the upregulation of NLRP3 and IL-1β in active 
disease.  Following on from these results the aim of Chapter 5 was to examine the 
cellular localisation of NLRP3 and IL-1β, and the spatial interaction of NLRP3 and 
IL-1β in active disease.   
 
  
  
95 
 
5.2 RESULTS 
5.2.1 NLRP3 AND IL-1Β ANTIBODY OPTIMISATION 
In order to investigate the localisation of NLRP3 and IL-1β in colon tissue it was 
first necessary to establish the efficiency of the primary antibodies in human 
control tissues. The NLRP3 antibodies (ab17267 and ab16097, Abcam, 
Cambridge, MA, USA) demonstrated positive staining in the cytoplasmic regions 
of the stratified squamous epithelial layer of normal human tonsil (Figures 5-1 
and 5-2). In agreement, distinct NLRP3 expression has previously been reported 
for the stratified non-keratinizing squamous epithelium of the oral and 
oesophageal mucosa [268]. 
 The IL-1β antibody (ab9722, Abcam, Cambridge, MA, USA) demonstrated 
positive cytoplasmic staining  for the circulating immune cells, such as 
macrophages, lymphocytes and dendritic cells, localised to the paracortical zone 
of human lymph node tissue (Figures 5-1 and 5-2). In agreement, positive IL-1β 
staining has previously been reported within the germinal centre, paracortical 
and mantle zones of human lymph node tissue during infection [269]. 
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Figure 5-1: Representative immunohistochemistry images of NLRP3 
and IL-1β localisation in human control material 
All sections were paraffin embedded, cut into 5 μm sections and mounted on 
superfrost plus slides. A and B) Localisation of NLRP3 (ab17267, Abcam, 
Cambridge, MA, USA) in human tonsil, diluted 1:300. C and D) Localisation of IL-
1β (ab9722, Abcam, Cambridge, MA, USA) in human lymph node tissue, diluted 
1:300. Scale bars represent 50 μm for the 400X and 200 μm for the 100X 
magnification.  
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Figure 5-2 (previous page): Representative immunofluorescence 
confocal images of NLRP3 and IL-1β localisation in human control 
material 
All sections were paraffin embedded, cut into 5 μm sections and mounted on 
superfrost plus slides. A) Localisation of NLRP3 (ab17267, Abcam, Cambridge, 
MA, USA) in normal human tonsil, diluted 1:100 and visualised using Alexa 
Fluor®647 conjugated goat anti-mouse IgG (red). B) Localisation of NLRP3 
(ab16097, Abcam, Cambridge, MA, USA) in normal human tonsil, diluted 1:100 
and visualised using Alexa Fluor®647 conjugated goat anti-mouse IgG (red). C) 
Localisation of IL-1β (ab9722, Abcam, Cambridge, MA, USA) in human lymph 
node tissue, diluted 1:100 and visualised using Alexa Fluor®555 conjugated goat 
anti-rabbit IgG (green). Nuclei were stained with 4’ ,6 diamidino-2-phenylindole 
(DAPI, blue). Scale bars represent 100 μm for both the 100X and 400X 
magnification. 
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5.2.2 COLONIC LOCALISATION OF NLRP3  
The expression of NLRP3 increased with disease activity in UC and CD (Figures 
5-3 and 5-4). In active UC, prominent cytoplasmic staining was present in the 
neutrophils and other immune cells of the lamina propria while diffuse staining 
was evident in the epithelial cell region. Consistent with pathology reports, 
biopsy sections from active UC patients were characterised by an influx of lamina 
propria immune cells concentrated around regions of crypt distortion or mucosal 
inflammation.  
For active ileal and colonic CD, the reported influx of lamina propria immune cells 
seen in active UC was not evident, however the intensity of staining within lamina 
propria immune cells was comparable. Moderate cytoplasmic staining of NLRP3 
was also evident in the epithelial cell layer including around goblet cells. Similar 
expression patterns were observed for both the colon and ileum biopsies in active 
ileal CD. 
In the normal colon, scattered lamina propria immune cells demonstrated 
cytoplasmic NLRP3 expression and minimal NLRP3 staining was noted in the 
epithelial cell layer of the intestinal crypts. Remission UC and CD had similar 
NLRP3 staining patterns with the occasional lamina propria immune cells 
presenting with NLRP3 expression while epithelial NLRP3 expression was 
unremarkable. 
Quantitative analysis of NLRP3 staining indicated that NLRP3 expression is 
higher in active UC (normal vs active UC, p<0.001) and active ileal CD (normal vs 
active ileal CD, p=0.004) than in the normal colon (Figure 5-7A). Remission of 
both UC (active UC vs remission UC, p<0.001) and ileal CD (active ileal CD vs 
remission CD, p=0.004) but not colonic CD result in a reduction of NLRP3 
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expression. Interestingly, NLRP3 expression levels for disease in remission are 
similar to normal colon levels which is in contrast to the reduction of lL-1β 
expression seen when UC or CD experience disease remission (Figure 57-B). 
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Figure 5-3: Representative immunohistochemistry images of NLRP3 
expression in normal colon, active and remission UC, active ileal and 
colonic CD and remission CD. 
All biopsies were taken from the left colon (unless otherwise stated as ileum 
biopsy), paraffin embedded, cut into 5 µm sections and incubated with NLRP3 
(ab17267, Abcam, Cambridge, MA, USA) at a dilution of 1:300. Scale bars 
represent 200 µm for 100X and 50 µm for 400X magnification. 
 
Figure 5-4 (next page): Representative immunofluorescence confocal 
images of NLRP3 expression in normal colon, active UC and active 
ileal and colonic CD.   
All biopsies were taken from the left colon, paraffin embedded, cut into 5 μm 
sections and incubated with NLRP3 (ab17267, Abcam, Cambridge, MA, USA) at a 
dilution of 1:100 and visualised using Alexa Fluor®647 conjugated goat anti-
mouse IgG (red). Nuclei were stained with 4’ ,6 diamidino-2-phenylindole (DAPI, 
blue).  Scale bars represent 100 μm for both the 100X and 400X magnification. 
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5.2.3 COLONIC LOCALISATION OF IL-1ΒETA  
The expression of IL-1β was highly variable across all IBD phenotypes (Figures 
5-5 and 5-6). In the normal colon, high expression of IL-1β was observed within 
the epithelial cell layer of the mucosal crypts, including the cytoplasm of 
intestinal goblet cells. Unremarkable was the occasional immune cell within the 
lamina propria demonstrating cytoplasmic and/or nuclear IL-1β staining.  
In active UC, there was a marked increase in the number of lamina propria 
immune cells, which was consistent with histology pathology reports. Notable 
was the high proportion of lamina propria cells exhibiting dense cytoplasmic and 
nuclear IL-1β expression. This high IL-1β expression was not observed for cells 
within the epithelial layer of the intestinal crypts. Remission UC demonstrated a 
marked decrease in the intensity of IL-1β staining within cells of the lamina 
propria with no staining evident in the epithelial cell layer or near goblet cells. 
A slight increase in the number of lamina propria immune cells was observed in 
active ileal and colonic CD and is consistent with pathology reports. Cytoplasmic 
IL-1β staining was evident in a high proportion of lamina propria immune cells. 
Remarkable IL-1β expression was observed in the epithelial cells layer, notably 
the cytoplasm of goblet cells for ileal CD but not colonic CD. For active ileal CD, 
the expression of IL-1β was similar in both colon and ileum biopsies. In remission 
CD, IL-1β expression was unremarkable with only scattered staining evident in 
the lamina propria immune cells. The slightly diminished sensitivity in IL-1β 
staining observed in sections stained by immunofluorescence was attributed to 
the inability of immunofluorescence imagery to distinguish between cell borders 
and background tissue. 
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Quantitative analysis of IL-1β staining indicated that IL-1β expression is higher 
in active UC (normal vs active UC, p=0.002) and active ileal CD (normal vs active 
ileal CD, p=0.002) but not colonic CD (normal vs active colonic CD, p>0.99, not 
significant). A reduction in the expression of IL-1β was evident when both UC 
(active UC vs remission UC, p<0.001) and ileal CD (active ileal CD vs remission 
CD, p<0.001; active colonic CD vs remission CD, p=0.87) were in clinical 
remission (Figure 5-7B). Interestingly, disease in remission IL-1β levels were 
lower than those seen in the normal colon (normal colon vs UC remission, 
p=0.004; normal colon vs CD remission, p=0.149, not significant). 
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Figure 5-5: Representative immunohistochemistry images of IL-1β 
expression in  normal colon, active UC, remission UC, active ileal and 
colonic CD and remission CD. 
All biopsies were taken from the left colon (unless stated as ileum biopsy), 
paraffin embedded, cut into 5 μm sections and incubated with IL-1β (ab9722, 
Abcam, Cambridge, MA, USA) at a dilution of 1:300. Scale bars represent 50 μm 
for 400X and 200 μm for 100X magnification. 
 
 
Figure 5-6 (next page): Representative immunofluorescence confocal 
images of IL-1β expression in normal colon, active UC and active ileal 
and colonic CD.  
All biopsies were taken from the left colon, paraffin embedded, cut into 5 μm 
sections and incubated with IL-1β (ab9722, Abcam, Cambridge, MA, USA. 1:100 
dilution) and visualised using Alexa Fluor®555 conjugated goat anti-rabbit IgG 
(green). Nuclei were stained with 4’ ,6 diamidino-2-phenylindole (DAPI, blue).  
Scale bars represent 100 μm for both the 100X and 400X magnification. 
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Figure 5-7: Quantification of NLRP3 and IL-1β 
immunohistochemistry staining in biopsy sections from normal and 
IBD patients 
A) Quantitative analysis of NLRP3 expression in sections from normal colon 
(total number of images analysed=10), active UC (n=91), remission UC (Rem. 
UC, n=21), active ileal CD (n=25), active colonic CD (n=17) and remission CD 
(Rem. CD, n=18). B) Quantitative analysis of IL-1β expression in sections from 
normal colon (n=24), active UC (n=46), remission UC (Rem. UC, n=20), active 
ileal CD (n=48), active colonic CD (n=16) and remission CD (Rem. CD, n=18). 
Paraffin embedded left colon mucosal biopsies were analysed by 
immunohistochemistry and the optical intensity of DAB staining due to primary 
antibody was determined using FIJI software. All data are presented as mean + 
standard deviation. Statistical significance was evaluated using Dunn’s multiple 
comparison one-way analysis of variance (ANOVA). The significance threshold 
was p<0.05. 
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5.2.4 COLOCALISATION OF NLRP3 AND IL-1ΒETA IN ACTIVE UC 
AND CD 
Immunofluorescence confocal microscopy was performed to assess the spatial 
relationship of NLRP3 to IL-1β within the cells of the lamina propria. Manders 
coefficients (M1 and M2) were used to evaluate the reciprocal association ratio 
between fluorescence markers with values ranging from 0.5 to 1.0 indicating a 
positive association. Pearson’s correlation coefficient was used to describe the 
correlation of the intensity distribution between channels. Values range from -1 
to 1 and indicate the strength of the negative or positive correlation [270]. 
For normal colon, a high proportion of colocalisation between NLRP3 and IL-1β 
was evident within the lamina propria immune cells (Figure 5-8). Quantification 
of Manders coefficients confirmed a positive association between NLRP3 and IL-
1β (M1, NLRP3:IL-1β = 0.81 + 0.06; M2, IL-1β:NLRP3 = 0.82 + 0.06) which 
indicates a similar contribution of one to the other (Figure 5-9A). 
Manders coefficients demonstrated less colocalisation of NLRP3 to IL-1β in active 
UC (M1, NLRP3:IL-1β = 0.67 + 0.04; M2, IL-1β:NLRP3 = 0.61 + 0.09) when 
compared to the normal colon biopsies. Interestingly the appearance of a y-
dominated scattergram suggests increased IL-1β production without 
concomitant increases in NLRP3 (Figure 5-8). The lack of correlation between 
NLRP3 and IL-1β in active UC is confirmed by the near zero (0.03) Pearson 
correlation coefficient (Figure 5-10). 
For active CD, the colocalisation of NLRP3 and IL-1β was stronger in ileal CD (M1, 
NLRP3:IL-1β = 0.78 + 0.05; M2, IL-1β:NLRP3 = 0.80 + 0.05; Pearson’s 
correlation coefficient = 0.29) than in colonic CD (M1, NLRP3:IL-1β = 0.63 + 
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0.05; M2, IL-1β:NLRP3 = 0.66 + 0.05; Pearson’s correlation coefficient = 0.22) 
(Figure 5-9C, Figure 5-9D and Figure 5-10). 
 
  
Figure 5-8 (next page): Representative co-immunostaining images of 
NLRP3 (red)  and IL-1b (green) in normal colon and active UC and 
active CD.  
Parrafin embedded colon biopsies were simultaneously stained with NLRP3 
(ab16097, Abcam, Cambridge, MA, USA)  and IL-1β (ab9722, Abcam, Cambridge, 
MA, USA) and visualised using Alexa Fluor®647 conjugated mouse anti-goat (red) 
and Alexa Fluor® 555 conjugated rabbit anti-goat (green) respectively.  Nuclei 
were stained with 4’ ,6 diamidino-2-phenylindole (DAPI, blue). The 2D histogram 
visualises the overall relationship of channel intensities for homologous pixels. 
The coordinates of the scattergram are the channel (CH) intensities of NLRP3 
(red-CH1-x) and IL-1β (green-CH2-y) within each pixel. The value at each 
location indicates the incidence of the combination.  Scale bar = 50 μm for 400X 
magnification. 
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Figure 5-9: Manders colocalisation coefficients (M1 and M2) for A) 
normal colon, B) active UC, C) active colonic CD, D) active ileal CD.  
Each data set was compiled from lamina propria regions of interest (ROI), from 
(n=20 images) 400X images, where averages are presented as mean + standard 
deviation. The significance threshold was p<0.05. 
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Figure 5-10: Pearson’s correlation coefficients for normal colon, 
active UC and active CD. 
Each data set describes the fluorescence intensity distribution between channels 
and was compiled from lamina propria regions of interest (ROI), from (n=20 
images) 400X images, where averages are presented as mean + standard 
deviation. Significance was tested using one way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison test. The significance threshold was 
p<0.05. 
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5.3 DISCUSSION 
This study describes the colonic localisation of NLRP3 and IL-1β in remission and 
active IBD and provides evidence that suggests both NLRP3 inflammasome-
dependent and independent processes contribute to IL-1β production.  
In normal colon, IL-1β was localised to the epithelial layer and generally absent 
from the lamina propria immune cells, while NLRP3 expression was generally 
present at low levels in the lamina propria immune cells. With disease activity, 
the expression of IL-1β unexpectedly shifted from the epithelial cell layer to the 
lamina propria cells and the expression of both NLRP3 and IL-1β in the lamina 
propria immune cells intensified. Previously, NLRP3 expression has been 
demonstrated in granulocytes, such as neutrophils, dendritic cell, monocytes, 
epithelial cells, T cells and B cells, with subcellular distribution localisation 
mainly in the cytoplasm [268].  
Microscopic architectural abnormalities, inflammatory changes and the influx of 
lamina propria immune cells  are important features for discriminating normal 
mucosa from IBD [271]. During active UC, neutrophils dominate the lamina 
propria immune cell population and are often the effector cells surrounding 
epithelial damage or mucosal inflammation [272]. Consequently, many grading 
scales for histological assessment of inflammation in UC include the presence and 
locality of neutrophils [273-275]. Furthermore, the use of neutrophils as a 
marker of disease activity in UC is supported by leucocyte scanning studies [276, 
277].  
The lack of acceptable sensitivity, specificity, and reproducibility discourages 
diagnosis of CD based on the lamina propria infiltrate. Diagnosis of CD therefore 
relies on the presence of epithelioid granuloma, relatively unchanged crypts or 
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segmented distribution of crypt atrophy, crypt distortion together with 
discontinuous focal or patchy inflammation (skip lesions) and mucin 
preservation in the epithelium at an ulcer edge. Focal inflammation is often 
characterised by a small collection of inflammatory cells in otherwise normal 
mucosa [16, 17, 278]. Microscopic structural abnormalities and the influx of 
lamina propria immune cells are not features of normal mucosa. 
Immunofluorescence confocal microscopy demonstrated a high proportion of 
colocalisation between NLRP3 and IL-1β in normal mucosa however, in active UC, 
the contribution of NLRP3 to the overall production of bioactive IL-1β was 
reduced. Together, these results suggest that during normal gut homeostasis 
inflammasome-dependent caspase-1 is a major contributor to IL-1β production. 
In contrast, during inflammatory conditions serine proteases produced by the 
influx of neutrophils into the lamina propria are possibly the main source of 
bioactive IL-1β and caspase-1 has only a minor role. 
Inflammasome-independent processing of proIL-1β in acute inflammatory 
conditions is well established and has been shown to occur where neutrophils 
dominate the lamina propria cell populations. For instance, host resistance to 
disseminated candidiasis is provided by neutrophil derived proteinase 3 
activation of IL-1β and not caspase-1 activation [267, 279, 280]. Similarly, during 
acute arthritis, neutrophil derived proteinase 3 plays a dominant role in in the 
production of bioactive IL-1β [281]. Again, serine proteases from neutrophils 
drive the inflammation and production of mature IL-1β in a murine model of 
osteomyelitis [282, 283]. 
The administration of IL-1 blocking agents such as rilonacept (Arcalyst, 
Regeneron, Tarrytown, NY, USA),  canakinumab (Ilaris, Novartis, Basel, 
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Switzerland) and anakinra (Kineret, Amgen, Thousand Oaks, CA, USA) [151]  
have resulted in remarkable clinical outcomes for patients with hereditary 
periodic fever syndromes known Cryopyrin-associated periodic syndromes 
(CAPS). CAPS are a family of autosomal dominant diseases including, familial cold 
auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome, (MWS), and 
chronic infantile neurological, cutaneous and articular, (CINCA) syndrome and 
are associated with the gain of function in NLRP3, which causes continuous IL-1β 
secretion in the absence of an antagonist. The clinical severity of CAPs varies but 
in general all syndromes are characterised by recurrent fever, urticarial-like 
rashes and systemic inflammation [151]. More than 90 disease associated genetic 
variants of the NLRP3 gene have been identified for CAPS, the majority are 
autosomal dominant missense point mutations, located in exon 3, which encodes 
the NACHT domain [152]. 
The blockade of NLRP3 using selective small-molecule inhibitors has recently 
been the focus of much research. MCC950 has been shown to inhibit canonical 
and non-canonical NLRP3 inflammasome activation and reduce IL-1β production 
[284].  However based on the results from Chapter 5, in diseases such as UC 
where neutrophils dominate the lamina propria infiltrate blocking NLRP3 or 
caspase-1 may not reduce in vivo IL-1β levels.  Interestingly, in a murine model 
of arthritis dual blockage of both caspase-1 and proteinase 3 is seen as a potential 
anti-inflammatory therapeutic option [281]. 
Taken altogether, this study provides evidence for the inflammasome-dependent 
and independent processing of IL-1β during active UC. Future IBD research now 
needs to focus on assessing neutrophil derived IL-1β production and the 
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therapeutic potential of blocking both caspase-1 and neutrophil derived serine 
proteases in active UC.  
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CHAPTER 6 COLONIC LOCALISATION OF NLRP6 AND 
INTERACTION WITH MUC2 AND E-CADHERIN 
 
6.1 INTRODUCTION 
The Nod-like receptor pyrin-containing protein 6 (NLRP6), also known as 
PYPAF5, is a member of the nucleotide-binding oligomerisation domain (NOD)-
containing protein receptor (NLR) family  for which there are 23 human and 34 
mouse members [20, 70]. Evidence for NLRP6 inflammasome formation has been 
provided by in vitro work demonstrating the colocalisation of NLRP6 with ASC in 
the cytoplasm and the production of IL-1β [285]. In the murine system, NLRP6 
has been shown to regulate goblet cell mucin production and secretion, regulate 
self-renewal and proliferation [226], protect against chemical induced intestinal 
injury and tumorigenesis [129, 186, 286] and negatively regulate inflammasome 
signalling [130]. Despite all the proposed functions for NLRP6 the activating 
ligand still remains unknown. 
Epithelial cells are protected from bacterial, chemical and physical insults by a 
stratified layer of mucus. The main protein component of the mucus barrier, 
mucin 2 (MUC2) is produced within specialised goblet cells where it is stored 
within a highly organised array of vertically orientated microtubules and 
intermediate filaments known as the theca. The theca defines the outer limit of 
the storage granular zone and  separates granules from the remaining cytoplasm 
[287]. Evidence for the modulation of Muc2 production by the microbial ecology 
is provided firstly, by the reduction in goblet cell number and decreased rates of 
epithelial cell turnover in mice grown in germ-free conditions [1, 288] and 
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secondly, by the ability of bacterial ligands to induce Muc2 production in 
intestinal explant cultures [289].  
Intestinal goblet cells are functionally heterogeneous and have been shown to 
contribute to the regulation of innate immune defences [289-291]. Goblet cell 
associated antigen passages (GAP) cells endocytose soluble material from the 
intestinal lumen and are capable of translocating the antigen to underlying 
CX3CR1 positive dendritic cells which then migrate to draining lymph nodes [291-
293].  
Work by Birchenough et al [289] in murine explants have demonstrated that TLR 
ligands, LPS, its subcomponent lipid A, the synthetic triacylated lipopeptide 
P3CSK4, flagellin and the neurotransmitter acetylcholine analog carbachol (Cch) 
induce Muc2 secretion from goblet cells. Furthermore, lower crypt goblet cells 
were shown to secrete Muc2 in response to Cch but not TLRs while a sentinel 
goblet cell (SenGC) localised to the colonic crypt entrance endocytosed 
responsive TLRs but not Cch and was expelled from the epithelium. The expulsion 
of SenGCs was shown to be driven by NLRP6 inflammasome activation since 
intrarectal P3CSK4 treatment resulted in endocytosis of P3CSK4 but not 
expulsion of SenGCs.  The expelled SenGC triggered an intercellular signal via gap 
junctions and increased cytoplasmic Ca2+ that induced Muc2 secretion in 
adjacent responsive goblet cells. Compound exocytosis and cascading Muc2 
secretion represents a mechanism that shifts bacterial pathogens and prevents 
colonisation of intestinal crypts. In contrast, work by Wlodarska et al [187] found 
that genetic deletion of Nlrp6, Asc and Casp1/11 was  associated with a diminish 
intact mucus layer, goblet cell hyperplasia and abrogated mucin secretion 
suggesting defects in NLRP6 affect autophagy and mucin release. Interestingly, 
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the lack of an intact mucus layer was not a feature of the inflammasome deficient 
mice used by Birchenough et al [289]. 
Determining the role of NLRP6 in the pathogenesis of gastrointestinal diseases 
has been aided by the use of Nlrp6 knockout mice and models of chemically 
induced colitis, however many differences exist between murine colitis and 
human IBD and many questions still remain unanswered. Based on the available 
murine Nlrp6 data it is hypothesised that NLRP6 also regulates goblet cell mucin 
production and secretion in human IBD. Gene expression data presented in 
Chapter 3 highlighted the disease specific upregulation of NLRP6 in ileal CD. 
Following on from these results the aim of Chapter 6 was to examine the cellular 
localisation of NLRP6, its relationship to MUC2 and E-cadherin, and the impact of 
NLRP6 on MUC2 expression in human cell lines.  
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6.2 RESULTS 
6.2.1 NLRP6 ANTIBODY OPTIMISATION 
In order to investigate the localisation of NLRP6 in colon tissue it was first 
necessary to establish the efficiency of the NLRP6 antibody (NBP2-31372, Novus 
Biological, Littleton, CO, USA). Positive cytoplasmic and nuclear staining for 
NLRP6 was observed in the breast ductal/acinar epithelium of normal human 
breast tissue (Figures 6-1 and 6-2). This is consistent with the NLRP6 (NBP2-
31372), Novus Biological product information sheet (Appendix 7) which also 
demonstrates positive cytoplasmic and nuclear staining in the ductal region of 
formalin fixed paraffin embedded human breast tissue using 
immunohistochemistry analysis. 
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Figure 6.1 (previous page): Localisation of NLRP6 in normal human 
breast tissue as analysed by immunohistochemistry. 
Tissue was paraffin embedded and cut into 5 μm sections. The NLRP6 antibody 
(NBP2-31372, Novus Biological, Littleton, CO, USA) was diluted 1:300. Scale bars 
represent 200 μm for 100X and 50 μm for 400X magnification. 
 
 
Figure 6-2: Representative immunofluorescence confocal images of 
NLRP6 localisation  in normal human breast tissue 
All sections were paraffin embedded, cut into 5 μm sections and mounted on 
superfrost plus slides. Localisation of NLRP6 (NBP2-31372, Novus Biological, 
Littleton, CO, USA) in normal human breast  diluted 1:100 and visualised using 
Alexa Fluor®647 conjugated goat anti-rabbit IgG (red). Nuclei were stained with 
4’ ,6 diamidino-2-phenylindole (DAPI, blue). Scale bars represent 100 μm for 
both the 100X and 400X magnification. 
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6.2.2 COLONIC LOCALISATION OF NLRP6 
Immunohistochemistry and immunofluorescence confocal microscopy were 
used to determine the colonic localisation of NLRP6.  Prominent NLRP6 
expression was observed in the colon and ileum biopsies from active ileal CD 
patients. The high expression of NLRP6 was almost exclusively localised to the 
epithelial cell layer, including myofibroblasts, however a moderate number of 
neutrophils and monocytic linage cells residing in the lamina propria also 
exhibited high NLRP6 expression (Figures 6-3 and 6-4). 
In both, active colonic CD and remission CD, staining of the epithelial cell layer 
was unremarkable and only scattered NLRP6 expression was noted within the 
lamina propria immune cells. In the normal colon, moderate cytoplasmic NLRP6 
expression was present in the epithelial cell layer and only scattered staining was 
evident in lamina propria cells. In contrast, no cytoplasmic epithelial NLRP6 
expression was evident in active UC or remission UC. However, in active UC a 
moderate number of lamina propria cells expressed NLRP6 while in UC remission 
the expression was minimal. Quantitative analysis of NLRP6 
immunohistochemistry staining confirmed the high NLRP6 expression in ileal CD 
(active ileal CD vs active colonic CD, p<0.001; active ileal CD vs remission CD, 
p<0.001) (Figure 6-7A). 
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Figure 6-3: Representative immunohistochemistry images of NLRP6 
expression in  normal colon, active UC, remission UC, active ileal and 
colonic CD and remission CD.  
All biopsies were taken from the left colon (unless stated as ileum biopsy), 
paraffin embedded, cut into 5 μm sections and incubated with NLRP6 (NBP2-
31372, Novus Biological, Littleton, CO, USA) at a dilution of 1:200.  Scale bars 
represent 200 μm for 100X and 50 μm for 400X magnification. 
 
Figure 6-4 (next page): Representative immunofluorescence images 
of NLRP6 localisation in normal colon, active UC, active ileal and 
colonic CD.   
All biopsies were taken from the left colon, paraffin embedded, cut into 5 μm 
sections and incubated with NLRP6 (NBP2-31372, Novus Biological, Littleton, 
CO, USA, 1:100 dilution) and visualised using Alexa Fluor®647 conjugated goat 
anti-rabbit IgG (red). Nuclei were stained with 4’ ,6 diamidino-2-phenylindole 
(DAPI, blue).  Scale bars represent 100 μm for both the 100X and 400X 
magnification. 
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6.2.3 MUC2 ANTIBODY EFFICIENCY AND COLONIC LOCALISATION  
Immunohistochemistry and immunofluorescence confocal microscopy was used 
to determine the colonic localisation of MUC2. The efficiency of the MUC2 
antibody (H:300: sc15334, Santa Cruz, Dallas, Texas, USA) was confirmed by the 
consistent staining of goblet cells theca contents across all colon biopsy samples 
(Figures 6-5 and 6-6). 
The expression of MUC2 was found to be highly variable in distribution and depth 
of staining across all IBD phenotypes (Figures 6-5 and 6-6). In remission and 
active CD the architecture and packaging of MUC2 granules was highly organised 
and this structural organisation was lacking in active UC and in the normal colon 
(Figure 6-5). 
Normally colonic crypts contain smaller goblet cell theca containing less MUC2 in 
the lower crypts and larger MUC2 filled theca in the upper crypt [289]. 
Surprisingly, in active ileal CD, active colonic CD and remission CD large tightly 
packed theca containing MUC2 granules were observed along the entire crypt 
length and this overcrowding of goblet cells was often associated with crypt 
distortion.  
Quantitatively, the expression of MUC2 in active ileal CD was greater than in 
active UC (active ileal CD vs active UC, p=0.002) and the expression in both UC 
remission and active UC was less than that observed in the normal colon (normal 
vs remission UC, p<0.001; active UC vs remission UC, p=0.002). Overall, the 
active tissues of both UC and CD showed a higher variability in MUC2 expression 
as indicated by the increased standard deviation error bars (Figure 6-7B).  
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Figure 6-5: Representative immunohistochemistry images of MUC2 
expression in  normal colon, active UC, remission UC, active ileal and 
colonic CD and remission CD. 
All biopsies were taken from the left colon (unless stated as ileum biopsy), 
paraffin embedded, cut into 5 μm sections and incubated with a MUC2 rabbit 
polyclonal antibody (H:300: sc15334, Santa Cruz, Dallas, Texas, USA), at a 
dilution of 1:300. Scale bars represent 200 μm for 100X and 50 μm for 400X 
magnification. 
 
Figure 6-6 (next page): Representative immunofluorescence images 
of MUC2 localisation in normal colon, active UC, active ileal and 
colonic CD.   
All biopsies were taken from the left colon, paraffin embedded, cut into 5 μm 
sections and incubated with MUC2 (H:300: sc15334, Santa Cruz, Dallas, Texas, 
USA, 1:200 dilution) and visualised using Alexa Fluor®647 conjugated goat anti-
rabbit IgG (green). Nuclei were stained with 4’ ,6 diamidino-2-phenylindole 
(DAPI, blue). Scale bars represent 100 μm for both the 100X and 400X 
magnification. 
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Figure 6-7:  Quantification of NLRP6 and MUC2 
immunohistochemistry staining in biopsy sections from normal and 
IBD patients 
A) Quantitative analysis of NLRP6 expression in sections from normal colon 
(total number of images analysed=18), active UC (n=43), remission UC (Rem. 
UC, n=20, active ileal CD (n=34), active colonic CD (n=18) and remission CD 
(Rem. CD, n=12). B) Quantitative analysis of MUC2 expression in sections from 
normal colon (n=20), active UC (n=62), remission UC (Rem. UC, n=20), active 
ileal CD (n=24), active colonic CD (n=30) and remission CD (Rem. CD, n=30).  
Paraffin embedded left colon mucosal biopsies were analysed by 
immunohistochemistry and the optical intensity of DAB staining due to MUC2 
was determined using FIJI software. All data are presented as mean + standard 
deviation. Statistical significance was evaluated using Dunn’s multiple 
comparison one-way analysis of variance (ANOVA). The significance threshold 
was p<0.05. 
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Figure 6-8: Representative colocalisation images of NLRP6, MUC2 and 
E-cadherin  in normal colon biopsies.  
A) Parrafin embedded normal colon biopsies were stimultaneously stained with 
NLRP6 (red) (NBP2-31372, Novus Biological, Littleton, CO, USA) and MUC2 
(green) (F-2: sc-515032, Santa Cruz Biotechnology, Dallas, Texas, USA) and 
visualised using AexaFluor® 647 conjugated rabbit anti-goat and Alexa 
Fluor®555 conjugated mouse anti-goat respectively. B) Parrafin embedded 
normal colon biopsies were stimultaneously stained with NLRP6 (red) (NBP2-
31372, Novus Biologicals, Littleton, CO, USA) and E-cadherin (yellow) (NCH-
38;M2612, Dako North America, Carpinteria, CA, USA) and visualised using 
AexaFluor®647 conjugated rabbit anti-goat and Alexa Fluor®555 conjugated 
mouse anti-goat respectively. Nuclei were stained with 4’ ,6 diamidino-2-
phenylindole (DAPI, blue). Spatial intensity profile is indicated by the dotted line. 
Images are 400X and scale bars = 50 µm.  
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6.2.4 COLOCALISATION OF NLRP6 WITH MUC2 AND E-CADHERIN  
To determine the spatial relationship of NLRP6 to the major mucin protein, MUC2 
and the epithelial cell marker, E-cadherin, biopsies were double stained for 
NLRP6 and MUC2 or NLRP6 and E-cadherin and examined using 
immunofluorescence confocal microscopy. Using visual inspection and spatial 
profiling there was no evidence of NLRP6 colocalising with MUC2 in active ileal 
CD biopsies (Figure 6-9A) however strong colocalisation was evident with E-
cadherin (Figures 6-9B and 6-9C). Previously,  losses in E-cadherin have been 
associated with active disease processes [294], however this was not observed in 
active ileal CD. Additionally, in ileal CD a high proportion of upper goblet cells cell 
exhibited high cytoplasmic NLRP6 expression were observed while other goblet 
cells remained NLRP6 negative (Figure 6-9A). In accordance with mouse studies 
by Birchenough et al [289] it is proposed that the high NLRP6 expressing goblet 
cells would be eventually expelled from the epithelium in a NLRP6 dependent 
manner. In the normal colon biopsies, NLRP6 was found to colocalise with E-
cadherin and not MUC2 and the apical goblet cell specific expression of NLRP6 
was not evident (Figure 6-8).   
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Figure 6-9 (previous page): Representative colocalisation images of 
NLRP6, MUC2 and E-cadherin  in ileal CD biopsies.  
A) Parrafin embedded active ileal CD (left colon) biopsies) were stimultaneously 
stained with NLRP6 (red) (NBP2-31372, Novus Biological, Littleton, CO, USA) 
and MUC2 (green) (F-2: sc-515032, Santa Cruz Biotechnology, Dallas, Texas, 
USA) and visualised using AexaFluor®647 conjugated rabbit anti-goat and Alexa 
Fluor®555 conjugated mouse anti-goat respectively. Solid lines indicates goblet 
cell with high NLRP6 expression. Dashed line indicates goblet cells with no 
NLRP6 expression. B) Parrafin embedded active ileal CD (left colon) biopsies 
were stimultaneously stained with NLRP6 (red) (NBP2-31372, Novus 
Biologicals, Littleton, CO, USA) and E-cadherin (yellow) (NCH-38;M2612, Dako 
North America, Carpinteria, CA, USA) and visualised using AexaFluor®647 
conjugated rabbit anti-goat and Alexa Fluor®555 conjugated mouse anti-goat 
respectively.  
C) Parrafin embedded active ileal CD (ileum) biopsies were stimultaneously 
stained with NLRP6 (red) (NBP2-31372, Novus Biologicals, Littleton, CO, USA) 
and E-cadherin (yellow) (NCH-38;M2612, Dako North America, Carpinteria, CA, 
USA) and visualised using AexaFluor®647 conjugated rabbit anti-goat and Alexa 
Fluor®555 conjugated mouse anti-goat respectively.  
Nuclei were stained with 4’ ,6 diamidino-2-phenylindole (DAPI, blue). Spatial 
intensity profile is indicated by the dotted line. Images are 400X and scale bars = 
50 µm. 
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6.2.5 THE INDUCTION OF NLRP6 IN COLONIC CELL LINES 
To examine the effect of NLRP6 on MUC2 expression, a known PPAR-γ agonist, 
rosiglitazone, in the absence of LPS priming was used to induce NLRP6 
expression in the human cell lines, LS174T and HT29.  
In the LS174T cell line, rosiglitazone at concentrations from 0.5-50 µM increased 
the expression of NLRP6 (p=0.01). The increase in NLRP6 expression resulted in 
repression  of MUC2 (p=0.002) and PPAR-γ expression (p=0.01). The expression 
of IL-1β and IL-18 remained unchanged despite the increase in NLRP6 expression 
(Figure 6-10).  
For the HT29 cell line, a 6-hour incubation of rosiglitazone at concentration 
between (1-100 µM) failed to induce NLRP6 expression. Interestingly, the 
expression of MUC2 increased without NLRP6 induction and the expression of IL-
1β reduced. The expression of PPAR-γ was unaffected by increasing 
concentrations of rosiglitazone (Figure 6-11).  
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Figure 6-10: mRNA expression of NLRP6, MUC2, PPAR-γ, IL-1β and 
IL-18 in LS174T cells treated with Rosiglitazone. 
Rosiglitazone of varying concentrations (5-50,000 nM) was used to induce 
NLRP6 expression in HT29 cells. Results are relative to ethanol-treated control 
cells (Un.=unstimulated) and normalised to the housekeeping gene, EEF2. Data 
are expressed as the mean + SEM of 3 independent experiments carried out in 
duplicate. Differences between group means were assessed using one-way 
analysis of variance (ANOVA). The significance threshold was p<0.05. 
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Figure 6-11: mRNA expression of NLRP6, MUC2, PPAR-γ, IL-1β and 
IL-18 in HT29 cells treated with Rosiglitazone. 
Rosiglitazone of varying concentrations (1-100 µM) was used to induce NLRP6 
expression in HT29 cells. Results are relative to ethanol-treated control cells 
(Un.=unstimulated) and normalised to the housekeeping gene, EEF2. Data are 
expressed as the mean + SEM of 3 independent experiments carried out in 
duplicate. Differences between group means were assessed using one-way 
analysis of variance (ANOVA). The significance threshold was p<0.05. 
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6.3 DISCUSSION 
This study describes the colonic localisation of NLRP6 and MUC2 expression in 
IBD and identifies a NLRP6 expressing goblet cell located predominantly in the 
upper portion of the intestinal crypt, which suggests a possible role for NLRP6 in 
goblet cell expulsion. 
In colonic and ileum biopsies from active ileal CD, abundant NLRP6 expression 
was demonstrated in the epithelial cell layer, colonic myofibroblasts and immune 
cells of the lamina propria. In contrast, NLRP6 in UC was localised to the influx of 
immune cell within the lamina propria and absent from the epithelial cell layer. 
Murine Nlrp6 is highly expressed in both the small and large intestine [129, 226] 
including the intestinal epithelial cells [129, 186, 226], colonic myofibroblasts 
[226], granulocytes, T cells and macrophages [286] but is reduced in mice 
adenocarcinoma [226]. Expression data for NLRP6 in humans is limited, however 
RNA sequencing and antibody-based profiling of non-diseased human gut tissue 
have defined NLRP6 expression to be restricted to the duodenum, jejunum/ileum 
[295] and absent from the colon [295, 296].  
Colonic myofibroblasts are a major source of modulators of the Wnt signalling 
pathway which governs approximately 80 genes involved in the differentiation, 
proliferation and upward migration of gastrointestinal epithelial cells. In mice, 
the presence of NLRP6 expression in colonic myofibroblasts has previously been 
disputed however the results of this study are consistent with Normand et al 
[226]. 
NLRP6 was localised to the goblet cell cytoplasm and did not colocalise with 
mucin 2 granules within the theca. Intestinal goblet cells have been shown to be 
functionally heterogeneous [289-291]. Work by Birchenough et al [289] 
  
141 
 
proposed that the upper crypt, apical orientated goblet cells are similar to SenGC 
and NLRP6 directs MUC2 release and goblet cell expulsion. In accordance, this 
study also identified an upper crypt NLRP6 expressing goblet cell in active ileal 
CD, suggesting the possibility of a NLRP6 driven goblet cell release. The 
compound exocytosis of goblet cells and cascading MUC2 secretion are thought 
to be a mechanism for shifting bacteria away from the crypt opening. In contrast 
to Birchenough et al [289], many high-NLRP6 expressing goblet cells were 
present along the crypt length suggesting constant goblet cell expulsion and 
MUC2 secretion in active ileal CD. Interestingly, CD is often associated with a 
thickened mucus layer that is constantly being secreted while in UC the mucus 
layer is thinned which fails to prevent penetration by pathogens [11, 297].  
The induction of NLRP6 using rosiglitazone failed to increase the expression of 
MUC2 in LS174T cells. Rosiglitazone is a PPAR-γ synthetic agonist and in the 
colon has the potential to exert an anti-inflammatory effect [298]. The repression 
of MUC2 could therefore be due to minimal bacterial activity and unrelated to 
NLRP6 activity. Similarly, the increased MUC2 expression in HT29 cells was 
probably not a result of NLRP6 activity since rosiglitazone failed to induce NLRP6.  
NLRP6 was found to colocalise with E-cadherin in colon and ileum biopsies from 
ileal CD patients. E-cadherin is the major constituent of adherens junctions and is 
required for the maintenance of architecture, cellular integrity, mediation of 
intercellular associations and cell polarisation [299, 300]. Cellular adhesion, 
maturation and the correct placement of paneth and goblet cells is dependent on 
the proper expression of E-cadherin [300]. E-cadherin  has been shown to recruit 
Ras-related C3 botulinum toxin substrate 1 (Rac1) which anchors the E-cadherin-
catenin complex to actin thereby stabilising the cellular structure [301]. 
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Previously, only transient losses of E-cadherin have been associated with active 
CD, with more pronounced losses being seen in active UC [294, 302, 303]. Given 
the high expression of NLRP6 in colonic myofibroblasts and the tight association 
with E-cadherin, one can speculate that NLRP6 may play a role in epithelial cell 
migration and goblet cell exocytosis as a mechanism for shifting bacteria away 
from the crypt opening.  Indeed, microbial dysbiosis and depletion of a number 
of commensal bacteria is a common finding in UC and CD. Ileal CD is often 
associated with increases in Enterobacteriaceae (such as adherent-invasive 
strains of Escherichia coli) and Ruminococcus gnavus populations and a decrease 
in Faecalibacterium and Roseburia [189-193, 304]. Interestingly, microbial 
population remain unaltered with CD disease remission while UC remission 
induces a microbial population comparable to normal populations [191]. Taken 
altogether, this study has provided evidence for a sentinel like goblet cell 
localised to the upper crypt that directs goblet cell expulsion in a NLRP6 
dependent manner. 
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CHAPTER 7 GENERAL DISCUSSION 
 
7.1 DISCUSSION 
A contributing factor in the development of intestinal disease is divergent 
immune responses to commensal bacteria which promote inflammatory 
pathways that perpetuate chronic inflammation. Since their discovery in 2002, 
inflammasome complexes have emerged as key regulators of innate immune 
responses in both health and disease. An accessible framework for investigating 
the role of inflammasomes in the development of gastrointestinal disease has 
been provided by murine models of colitis. The increased susceptibility to 
chemically induced colitis and disease exacerbation in knockout mice with 
genetic defects in inflammasome related genes highlights the importance of 
inflammasomes to maintaining mucosal homeostasis. Similar studies 
investigating the role of inflammasomes in human IBD are currently lacking. This 
study addresses gaps in the literature by examining the overall expression 
profiles  of inflammasomes in human colitis. 
When considering the results contained within this thesis it is worth noting that 
while UC and CD are grouped under the IBD umbrella they do however, present 
with contrasting clinical and histological features and divergent disease 
progression. Crohn’s disease is characterised by discontinuous and transmural 
inflammation and the disease is often complicated by rectal sparing, fistulising 
disease, bowel strictures, luminal narrowing and abscesses.  While in UC, the 
inflammation is continuous and confined to the mucosa and submucosa layers 
[11, 297]. Additionally, the mucus layer is thickened in CD and thinned in UC [10]. 
  
144 
 
Chapter 3 details the mRNA expression of inflammasome components in 
quiescent and active UC and CD. These results demonstrated the upregulation of 
inflammasome forming receptors, inflammasome components and bacterial 
sensors which suggests activation of the inflammasome complex. The 131-fold 
increase in NLRP6 expression specific to active ileal CD was an exciting and novel 
finding and is the focus of research presented in Chapter 6. The increased 
expression of IL-1β was consistent with disease activity and the pathological 
nature of IL-1β. Worth noting is the upregulation of IL-1β was concomitant with 
increased mRNA of other core inflammasome receptors such as AIM2, NLRP1, 
NLRP3 and NLRP6 which makes it impossible to ascertain the contribution of 
each to the overall production of IL-1β. Indeed, NLRP3 showed the strongest 
correlation with IL-1β in both active UC and CD. Interestingly, the correlation of 
NLRP6 with IL-1β and IL-18 was minimal in active disease. The upregulation of 
IL-1β and downregulation of PPAR-γ are well established features of disease 
activity and confirm the reliability of the mRNA results presented in this study. 
Chapter 4, details the localisation of AIM2 in colonic biopsies obtained normal 
quiescent and active disease. The overall high expression of AIM2 in the epithelial 
cell and lamina propria immune cells across all IBD phenotypes indicates AIM2 is 
a key player in orchestrating heightened innate immune responses. The cell 
specific expression of AIM2 in the intraepithelial lymphocytes is an exciting 
discovery and suggests a sentinel like function and regulatory role for AIM2. 
Exploring the role of AIM2 in intraepithelial lymphocytes should be the focus of 
further research. 
Results from Chapter 3 demonstrated an increase in the expression of NLRP3 in 
active UC and CD. Chapter 5, details the cellular localisation of NLRP3 and its 
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spatial relationship to IL-1β. Unlike AIM2, the localisation of NLRP3 in active 
disease followed a more restricted pattern and was predominantly present in the 
immune cells of the lamina propria. Interestingly, the epithelial expression of IL-
1β observed in the normal colon shifted to cells of the lamina propria during 
active disease conditions.  
NLRP3 is regarded as a global inflammasome sensor, and caspase-1 dependent 
production of bioactive IL-1β occurs in response to pathogenic, sterile and 
cellular stress activators. IL-1β is responsible for many of the clinical symptoms 
such as fever, hypotension, pain and appetite suppression that patients 
experience during active disease. Locally, IL-1β can induce cytokine production,  
enhance T cell activation and antigen recognition, and direct neutrophils to the 
site of injury or infection [50, 204, 205]. When considering the findings of the 
colocalisation analyses it is first important to understand the histological 
differences between active UC and active CD.  Neutrophil influx into the lamina 
propria is a common feature of active UC and rarely seen in active CD.  As 
expected, in the normal colon, inflammasome dependent caspase-1 was found to 
contribute to the production of mature IL-1β. Surprising and novel to this 
research was the reduced contribution of the NLRP3 inflammasome to IL-1β 
production in active UC. Given the dominance of a neutrophil lamina propria cell 
population in active UC, it is possible that neutrophil derive serine proteases 
contribute more than the NLRP3 inflammasome to the overall IL-1β production 
(Figure 7-1).   
Chapter 6 details research carried on from the disease specific upregulation of 
NLRP6 in ileal CD. Previous murine work suggests NLRP6 is multifaceted, and has 
the ability to regulate goblet cell mucin production and secretion, regulate 
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epithelial self-renewal and proliferation, protect against chemical induced 
intestinal injury and tumorigenesis, and negatively regulate inflammasome 
signaling. With all of this in mind, the research began by examining the 
localisation of NLRP6 and MUC2 in human IBD. The prominent expression of 
NLRP6 in ileal CD was localised to the colonic epithelial cell layer, myofibroblasts, 
neutrophils and monocytic lineage cells of the lamina propria. Previously, NLRP6 
expression has been described as being absent from the human colon [295], so to 
be able to confirm the expression with immunohistochemistry and 
immunofluorescence confocal microscopy was an important step in the research 
process. The lack of colocalisation with the major mucin protein, MUC2 and the 
identification of an apical goblet cell expressing NLRP6 suggested a role for 
NLRP6 in mucin 2 release. In comparison with murine studies Birchenough et al 
[289] identified a sentinel goblet cell localised to the crypt opening which 
undergoes expulsion and compound exocytosis in a NLRP6 dependent manner. 
The overlap in fluorescence intensity of NLRP6 and the epithelial cell marker, E-
cadherin, and the expression in myofibroblasts is intriguing and possibly 
indicates a role for NLRP6 in epithelial positioning and migration.  
The results of Chapter 6 provided evidence for the emerging disparity between 
human colitis and chemically induced murine colitis. One of the most striking 
contrasts lies in the activity of the cytokine IL-18. In the murine system the 
induction of intestinal IL-18 has been shown to be to be NLRP6 dependent [225] 
and Nlrp6 deficiency to be related to low levels of IL-18 [129, 186]. This study 
found no change in the expression of IL-18 in active UC or active CD despite 
fluctuations in the expression of NLRP6. Taken together, our results suggest IL-
18 expression is not NLRP6 dependent.  
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In 2002, Grenier et al [285] provided in vitro evidence for the colocalisation of 
NLRP6 and ASC, which formed punctuated cytoplasmic structures, and the 
production of IL-1β. However the lack of correlation between NLRP6 and IL-1β 
or IL-18 demonstrated in Chapter 3 raises the possibility of NLRP6 functioning 
independently of inflammasome formation and IL-1β production (Figure 7-2).  
In Summary, this study demonstrates two important features of inflammasome 
activity. Firstly the hierarchical mRNA upregulation of multiple inflammasome 
complexes in active UC and CD. Secondly, the variations in cellular location of 
inflammasomes in the colonic mucosa. Taken together, the cell specific functions 
of individual inflammasome complexes and their cooperation can now be 
regarded as key events to orchestrating an effective innate immune response. 
Indeed, activation of the AIM2, NLRP3 and NLRC4 inflammasomes is known to 
occur upon challenge with Listeria monocytogenes and Candida albicans [118, 
305-308].  
In conclusion, these results have provided an insight into the activity of 
inflammasome in human IBD. Neutrophil-derived serine proteases can now be 
regarded as a possible source of bioactive IL-1β in active UC, and NLRP6 can now 
be considered a potential marker for distinguishing ileal CD from colonic CD and 
terminal ileum involved UC.   
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Figure 7-1: Production of IL-1β in the normal colon and active UC 
During normal colonic conditions NLRP3 inflammasome dependent caspase-1 is 
the main contributor to bioactive IL-1β production. In active UC, it is proposed 
that both inflammasome-dependent caspase-1 and neutrophil-derived serine 
proteases contribute to the overall production of IL-1β. 
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Figure 7-2: Activity of NLRP6 in ileal CD  
The increase in NLRP6 mRNA and protein levels in ileal CD represents a possible 
dual function of NLRP6 at the mucosal surface. It is proposed that NLRP6 is 
primarily a bacterial sensor of a yet to be determined pathogenic ligand. During 
high pathogenic loads, NLRP6 influences the release of mucin 2 in an NLRP6-
inflamasome-independent manner. The increase in mucus production aids the 
removal of pathogen from the mucosal surface. 
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7.2 LIMITATION OF THIS STUDY 
This study was reliant on the continued collection of biopsy samples from UC, CD 
and control patients. Several factors during this process have been identified as 
affecting the total number of biopsies received, and are detailed below in 
chronological order. 
The task of patient recruitment was given to nursing staff at both the Launceston 
General Hospital and the Calvary based St Vincent’s hospital. Meetings were 
regularly undertaken to ensure staff were aware of the study, the patient 
exclusion criteria, informed consent documentation and biopsy collection. 
However due to the rotational nature and high proportion of casual staff it was 
difficult to inform all staff. The reluctance to recruit possible participants was 
most likely a reflection of overworked staff and a lack of information about the 
study. Interestingly, when staffing was consistent more biopsy samples were 
collected and a decline was noted when these staff were on annual leave. 
During the colonoscopy procedure, patients who provide informed consent were 
often found to be either, in remission or with disease in its entirety and this led 
to confusion regarding correct biopsy collection. These biopsies did however 
contributed to the overall numbers for descriptive statistics but were unsuitable 
for comparative analyses.  
Degraded RNA was the main reason for exclusion of collected biopsy samples and 
was attributed to delayed preservation of biopsy material. In addition, biopsy 
samples without informed consent paperwork resulted in biopsies being 
discarded. Ideally, having the collection site and laboratory in the same facility 
would allow for better participation of scientific staff/students in the patient 
recruitment process.  
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Additionally, budget restrictions prevented whole transcriptome sequencing of 
IBD patients and therefore failed to provide the depth needed to identify 
population based SNPs specific to ileal CD or active UC. 
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7.3 FUTURE DIRECTION 
While this study has been important for determining overall activity and cellular 
distribution of inflammasome components in active disease, the focus of future 
work should now be directed towards the cell specific action of individual 
inflammasome complexes. Cell culture provides a cost effective option for 
studying inflammasome activity and should be used in comparison with human 
derived colonic tissue wherever possible. 
Intraepithelial lymphocytes are positioned within the epithelial cell layer and can 
perform both sentinel and regulatory functions. Dysregulation of intraepithelial 
lymphocyte responses can disrupt mucosal barrier integrity and lead to disease 
pathology [309]. AIM2 is the only inflammasome complex to directly bind its 
activating ligand, dsDNA. dsDNA is therefore an ideal trigger for examining 
downstream AIM2 innate responses. Initial studies should include 
immunofluorescence confocal microscopy with intraepithelial lymphocyte cell 
markers. Isolation of colonic intraepithelial lymphocytes, challenge with dsDNA 
and measurements of cytokine levels would potentially identify downstream 
targets.  
The ability of NLRP3 to activate in response to a wide range of stimulants has 
raised the possibility of NLRP3 blockage as a potential therapeutic option. Indeed, 
small molecule inhibitors such as MCC950 have shown the ability to block NLRP3 
without affecting the activity of the other inflammasomes [284]. Based on this 
results presented in this study, blocking NLRP3 will not alleviate IL-1β mediated 
symptoms since IL-1β production is also a result of neutrophil-derived proteases. 
Future studies investigating NLRP3 in active UC should include 
immunofluorescence confocal microscopy with neutrophil-derived serine 
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protease markers to confirm their colocalisation with IL-1β. Isolation of colonic 
neutrophils, bacterial activation, blocking of individual proteases and measuring 
the effect on IL-1β and other cytokines would be useful in assessing the 
contribution of serine protease to downstream inflammatory pathways. 
Repeating similar investigations in human cell lines may be useful in determining 
the therapeutic benefit of blocking neutrophil-derived serine proteases in active 
UC. 
The disease specific upregulation of NLRP6 in ileal CD has the greatest potential 
for ground breaking research. Subsequent studies should examine possible 
activators of NLRP6 in human cell lines. Unique to future research is the 
availability of a local ileal CD population with increased NLRP6 expression. 
Collection of ileal biopsies for explant cultures would provide comparison with 
human cell lines and may provide insight into downstream pathways or possible 
treatment options.  
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STUDY 
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APPENDIX 5: SELECTION OF SUITABLE HOUSEKEEPING GENE FOR 
QRT-PCR NORMALISATION 
 
To determine a suitable housekeeping gene for gene expression normalisation, 
the mean absolute Ct values for four commonly used reference gene, EEF2, 
GAPDH, HPRT1 and ACTB were compared across the 5 disease groups. All of the 
housekeeping genes demonstrated PCR amplification (Figure A6-1), however 
EEF2 showed slightly less variability (standard deviation = 0.2328) (Table 7-1) 
across the disease groups and similar PCR amplification to patient samples and 
therefore was the gene chosen for normalisation. 
Figure A6-1: Mean absolute Ct values for the four housekeeping genes 
across the 5 disease categories 
 
Table 7-1: Descriptive statistics for absolute Ct values of the four 
housekeeping genes 
 EEF2 GAPDH HPRT1 ACTB 
Mean Ct 27.01 23.05 29.48 23.53 
Standard deviation  0.2328 0.2362 0.4446 0.3532 
Standard error of mean  0.1041 0.1056 0.1988 0.1579 
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APPENDIX 6: PRODUCT INFORMATION SHEET FOR THE AIM2 
ANTIBODY (AB93015, ABCAM, CAMBRIDGE, MA) 
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APPENDIX 7: PRODUCT INFORMATION SHEET FOR THE NLRP6 
ANTIBODY (NBP2-31372, NOVUS BIOLOGICAL, 
LITTLETON, CO, USA) 
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